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Scientific Opinion on the developmental neurotoxicity potential of 
acetamiprid and imidacloprid
1 
 
EFSA Panel on Plant Protection Products and their Residues (PPR)
2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
 
This Scientific Opinion, published on 21 February 2014, replaces the earlier version published on 17 December 
2013 . 
ABSTRACT 
 
The European Food Safety Authority asked the Panel on Plant Protection Products (PPR) and their residues to 
deliver  a  Scientific  Opinion  on  the  developmental  neurotoxicity  (DNT)  potential  of  the  neonicotinoid 
insecticides  acetamiprid  and  imidacloprid.  An  in  vitro  study  (Kimura-Kuroda  et  al.,  2012)  suggested  that 
excitation and/or desensitisation of nicotinic acetylcholine receptors (nAChRs) by these compounds might affect 
developing mammalian nervous systems as occurs with nicotine. To evaluate the DNT potential of acetamiprid 
and  imidacloprid,  the  PPR  Panel  scrutinised  the  open  literature,  the  draft  assessments  reports  and  dossiers 
submitted  for  approval.  The  Panel  concludes  that  both  compounds  may  affect  neuronal  development  and 
function,  although  several  methodological  limitations  have  been  identified.  Considering  the  available  DNT 
studies  for  imidacloprid  and  acetamiprid,  important  uncertainties  still  remain  and  further  in  vivo  studies 
following  OECD  test  guideline  (TG)  426  are  required  to  robustly  characterise  a  DNT  potential  and  dose-
response  relationships,  particularly  for  acetamiprid.  The  Panel  considers  that  current  ARfDs  may  not  be 
protective enough for the possible DNT of acetamiprid and imidacloprid and no reliable conclusion can be 
drawn  as  regards  the  ADI  for  acetamiprid.  More  conservative  reference  values  are  proposed  based  on  the 
analysis of the existing toxicological data. However, the current ADI for imidacloprid is considered adequate to 
protect  against  its  potential  developmental  neurotoxic  effects.  Limitations  of  the  in  vitro  system  used  by 
Kimura-Kuroda et al. (2012) prevent its current use as a screening tool in the regulatory arena. The PPR Panel 
encourages the definition of clear and consistent criteria at EU level to trigger submission of mandatory DNT 
studies, which could include development of an integrated DNT testing strategy composed of robust, reliable 
and validated in vitro assays and other alternative methods complementary to the in vivo TG 426 for assessing 
the DNT potential of substances. 
© European Food Safety Authority, 2013 
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SUMMARY 
 
Following a request from the European Commission, the EFSA Panel on Plant Protection Products 
and  their  Residues  (PPR Panel)  was  asked  to  deliver  a  Scientific  Opinion  on  the  developmental 
neurotoxicity (DNT) potential of the neonicotinoid insecticides acetamiprid and imidacloprid.  
Acetamiprid  and  imidacloprid  have  been  evaluated  under  the  criteria  of  Council  Directive 
91/414/EEC and approved in Regulation (EU) No 540/2011. In 2012, a paper was published (Kimura-
Kuroda et al., 2012) describing in vitro experiments performed with acetamiprid and imidacloprid. It 
suggested that excitation or desensitisation or both of nicotinic acetylcholine receptors (nAChRs) by 
these neonicotinoids might affect the developing mammalian nervous system as is known to occur 
with nicotine.  
To  evaluate  the  DNT  potential  of  acetamiprid  and  imidacloprid,  the  PPR  Panel  scrutinised  the 
information  available  on  the  two  neonicotinoid  compounds  in  the  open  literature  as  well  as  in 
toxicological  assessments  for  regulatory  purposes,  including  the  dossiers  submitted  for  approval 
within the EU.  
The following questions were identified by the European Commission and answered by the PPR 
Panel: 
Q1 Based on the available data, both in the scientific literature and in the toxicological dossier 
submitted for approval, do acetamiprid and imidacloprid exhibit developmental neurotoxic effects? 
Based on the available data, the PPR Panel concludes that both acetamiprid and imidacloprid show 
some  indications  of  DNT  potential.  Evidence  of  effects  on  offspring  from  a  developmental 
neurotoxicity study for imidacloprid in rats, submitted within the EU and the US-EPA assessment 
frameworks,  reported  decreased  pup  body  weights,  reduced  motor  activity  level  and  changes  in 
dimensions of brain structures (reduction in the thickness of corpus callosum and a decreased width of 
caudate/putamen).  The  DNT  study  for  acetamiprid,  carried  out  within  the  US-EPA  assessment 
framework, showed decreased pup body weights, reduced pup pre-weaning survival and decreased 
maximum  auditory  startle  response.  The  Panel  therefore  concludes  that  the  two  neonicotinoid 
compounds may affect neuronal development and function. However, there are limitations concerning 
the available evidence due to methodological issues and uncertainties as to whether or not neurotoxic 
effects in offspring occurred below doses eliciting maternal toxicity. 
Q2 Have acetamiprid and imidacloprid been assessed adequately for developmental neurotoxicity 
and if not, which further information would be required? 
 
Comprehensive toxicological databases are available for these two neonicotinoids. Toxicological in 
vivo studies include acute, subacute, subchronic, chronic, mutagenicity, carcinogenicity, reproduction 
and developmental studies carried out for the hazard characterisation of these compounds within the 
EU  regulatory  framework.  However,  available  DNT  studies  show  limitations.  A  DNT  study  on 
imidacloprid included data that may not be sufficient for a robust characterisation of dose-response, 
e.g.  for  changes  in  dimensions  of  brain  structures.  Regarding  the  DNT  study  performed  for 
acetamiprid, important endpoints such as motor activity or learning and memory, which are expected 
to  be  the  most  sensitive  DNT  endpoints,  could  not  be  adequately  assessed.  Moreover,  there  are 
uncertainties with respect to the conclusion of the study report concerning the No Observed Adverse 
Effect Level (NOAEL) based on reduced pup auditory startle response. Overall, in the opinion of the 
Panel, the study can only provide supportive evidence, but is inadequate for a robust characterisation 
of effects and dose-response of acetamiprid-induced DNT. Thus, the PPR Panel concludes that further 
good quality in vivo studies following OECD TG 426 are required to more properly characterise a 
DNT potential as well as associated dose-response relationships, particularly for acetamiprid.  
 Developmental neurotoxicity potential of acetamiprid and imidacloprid 
 
EFSA Journal 2013;11(12):3471  4 
Q3 Do the existing health-based guidance values provide adequate protection against any potential 
developmental  neurotoxicity  of  acetamiprid  and  imidacloprid  and  if  not  what  values  would  be 
necessary to provide such protection? 
 
Based on the indications provided by the available DNT studies and the associated uncertainties in 
establishment of the corresponding NOAELs, the Panel considers that the current ARfDs may not be 
protective enough for the possible developmental neurotoxicity of acetamiprid and imidacloprid. The 
same uncertainties do not allow to set a reliable ADI for acetamiprid. However, the ADI set for 
imidacloprid would provide adequate protection against its potential adverse effects on the developing 
nervous system. Accordingly, more conservative reference values are proposed based on the existing 
toxicological data.  
 
The  PPR  Panel  recommends  that  a  more  conservative  NOAEL  of  2.5  mg/kg  bw  per  day  for 
acetamiprid should be used as a point of departure for the derivation of ADI, ARfD and AOEL, which 
should all be set at 0.025 mg/kg bw per day. When new and more reliable DNT data are available, the 
point of departure can be revised.  
As  the  current  ARfD  and  AOEL  for  imidacloprid  may  not  be  protective  enough  for  potential 
developmental neurotoxicity of this active substance, the Panel also recommends to conservatively 
lower these reference values to the same level as the ADI (0.06 mg/kg bw per day). 
 
Q4 Do the approved neonicotinoids need further investigation to clarify the mechanism of action of 
the  nAChRs?  Should  all  neonicotinoids  be  tested  using  the  in  vitro  system  mentioned  in  the 
publication of Kimura-Kuroda et al. (2012)? 
 
The  PPR  Panel  considers  that  further  research  is  warranted  on  the  role  of  nAChRs  in  neuronal 
differentiation and maturation  to fully understand the potential  DNT induced by acetamiprid and 
imidacloprid. The in vitro system used in the study of Kimura-Kuroda et al. (2012) covers only very 
limited aspects of brain functions and its limitations currently prevent its use as a tool for screening 
developmental neurotoxicants in the regulatory arena. In particular, the in vitro system as proposed by 
this  study  requires  considerable  further  characterisation  and  should  be  investigated  to  assess  its 
relevance to the in vivo situation. To extend confidence in findings, provision of positive and negative 
controls and scrutiny of data for reliability and reproducibility are required. Only then should a test 
based on this system be considered as a possible screening tool for neurotoxicity potential. Moreover, 
the  Panel  recommends  that  further  studies  should  be  performed  using  the  culture  of  other  brain 
structures which also express nAChRs (hippocampus, entorhinal cortex, basal ganglia or thalamus) 
where  the  key  developmental  processes  such  as  neuronal  and  glial  proliferation,  migration, 
differentiation,  neurite  outgrowth,  synaptogenesis,  networking,  myelination  and  programmed  cell 
death may be evaluated. 
Based  on  the  overall  appraisal  of  existing  data,  revised  in  the  context  of  the  present  Scientific 
Opinion, the PPR Panel considers that in vitro tests currently cannot substitute for in vivo DNT tests. 
Besides, no in vitro test can be used to date to set health-based reference values. The complexity of 
neurodevelopmental  processes  does  not  allow  a  proper  assessment  at  the  cellular  level  and 
behavioural  outcomes  cannot  be  assessed  by  in  vitro  models.  However,  in  vitro  assays  may  be 
regarded as complementary to animal testing because they may provide better understanding of the 
cellular/molecular mechanisms involved in developmental neurotoxicity. As such, in vitro tests could 
be incorporated into a DNT testing strategy to obtain mechanistic information or for purposes of 
screening/prioritisation. Following the provision included in section 5.6.2 (“Developmental toxicity 
studies”) of the Commission Regulation n. 283/2013 on data requirements for active substances, the 
PPR Panel encourages the definition of clear and consistent criteria at EU level to trigger submission 
of mandatory DNT studies, which could include development of an integrated and cost-effective, 
tiered  testing  strategy  composed  of  robust,  reliable  and  validated  in  vitro  assays  and  alternative 
methods  complementary  to  the  in  vivo  test  guideline  426  for  assessing  the  developmental 
neurotoxicity potential of substances. Developmental neurotoxicity potential of acetamiprid and imidacloprid 
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BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
 
Acetamiprid and imidacloprid are neonicotinoid insecticides evaluated under the criteria of Council 
Directive 91/414/EEC and approved in Regulation (EU) No 540/2011. Recently a paper has been 
published in the scientific literature
4 suggesting that excitation or desensitisation or both of nicotinic 
acetylcholine receptors (nAChRs) by neonicotinoids may affect the developing mammalian nervous 
system as is known to  occur with nicotine. New data have now been evaluated  by the Rapporteur 
Member States for these substances (Greece for acetamiprid and Germany for imidacloprid). 
 
In their evaluation, Greece highlighted the need for further investigations to clarify the mechanism of 
action of acetamiprid and imidacloprid, while they accepted the conclusions reported in the study
4. 
On the other hand, Germany concluded that the study merely contributes to the explanation of cellular 
mechanisms  behind  the  neurotoxic  effects  of  nicotine  and  neonicotinoids  acetamiprid  and 
imidacloprid. The German reviewers did not agree with the conclusions of the published study. 
 
The following questions have been identified: 
 
Question  1:  Based  on  the  available  data  both  in  the  published  scientific  literature  and  in  the 
toxicological dossier submitted for approval, do acetamiprid and imidacloprid exhibit developmental 
neurotoxic effects? 
 
Question  2:  Have  acetamiprid  and  imidacloprid  been  assessed  adequately  for  developmental 
neurotoxicity and if not, what further information would be of value in this assessment? 
 
Question 3: Do the existing health-based guidance values provide adequate protection against any 
potential developmental neurotoxicity of acetamiprid and imidacloprid and if not what values would 
be necessary to provide such protection? 
 
Question 4: Do the approved neonicotinoids need further investigation to clarify the mechanism of 
action of the nAChRs? Should all the approved neonicotinoids be tested using the in vitro system 
mentioned in the publication of Kimura-Kuroda et al. (2012)? 
 
 
                                                       
4  Kimura-Kuroda  J,  Komuta  Y,  Kuroda  Y,  Hayashi  Kawano  H.  Nicotine-like  effects  of  the  neonicotinoid  insecticides 
acetamiprid  and  imidacloprid  on  cerebellar  neurons  from  neonatal  rats.  PloS  ONE  2012;  7  (2):  e32432.  doi: 
10.1371/journal.pone.0032432 
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ASSESSMENT 
1.  The active substances: general characterisation, mechanisms of action and metabolism. 
 
Acetamiprid (ACE) and imidacloprid (IMI) belong to the first generation of systemic neonicotinoid 
insecticides.  These  compounds  account  for  about  25 %  of  the  current  global  insecticide  market 
(Swenson and Casida, 2013). They are structurally similar to nicotine (see their chemical structure 
below): 
 
(E)-N
1-[(6-chloro-3-pyridyl)methyl]-N
2-cyano-N
1-methylacetamidine (ACE) 
 
 
(E)-N
1-1-[(6-chloro-3-pyridinyl)methyl]-N-nitroimidazolidin-2-ylideneamine (IMI) 
   
 
Nicotine 
 
  
 
Table 1:   Basic toxicological features of the three compounds 
  Nicotine  Imidacloprid  Acetamiprid 
Molecular Weight  162 (498
*) 
(Matta, 2007) 
255.7 
(Gervais, 2010) 
222.68 
(Abramovitch, 2002) 
Lethal/ near lethal dose 
for humans
5 
30-60 mg  
0.5-1.0 mg/kg bw adults 
(Gosselin, 1988). 
10 mg children (Arena, 
1974) 
 
< 44.6 ng/L (< 0.17 nM) 
Plasma concentration 5 h 
post-ingestion in an 
intensive care survivor 
(Mohamed, 2009) 
2.3-59.8 mg/L 
(10.3-268.7 µM)  
Serum concentration 
after acute poisoning 
(Imamura, 2010; 
Todani et al., 2008) 
Oral LD50 rat  50 mg/kg bw 
(Okamoto, 1994) 
500 mg/kg bw male  
380 mg/kg bw female 
(Gervais, 2010) 
417 mg/kg bw male 
314 mg/kg bw female 
(Greece, 2001) 
Oral LD50 mouse  3.34 mg/kg bw 
(Okamoto, 1994) 
130 mg/kg bw male  
170 mg/kg bw female 
(Gervais, 2010) 
198 mg/kg bw male 
184 mg/kg bw female 
(Singh, 2012) 
*Nicotine hydrogen tartrate salt. 
 
 
                                                       
5 No lethal doses for ACE or IMI have been identified in humans, but only plasma levels after acute poisoning. However, 
there are available lethal/near lethal dose of nicotine for human and children.  
See: http://www.inchem.org/documents/pims/chemical/nicotine.htm#DivisionTitle:7.2.1.1 Adults 
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Absorption, distribution, metabolism and excretion of ACE and IMI 
The  neonicotinoids  are  moderately  soluble  in  water,  non-ionised,  not  readily  hydrolysed  at 
physiological pH and biodegradable, thus they do not accumulate in mammals or through food chains 
(Tomizawa and Casida, 2003).  
 
Acetamiprid 
 
ACE is rapidly (Cmax was reached at 0.5-7 h) and extensively absorbed after single (1 or 50 mg/kg bw) 
(~96 %) and repeated (1 mg/kg bw) (> 60 %) oral administration. It is then distributed reaching the 
highest concentrations in liver, kidneys, adrenals and thyroid. Excretion is rapid, mainly via urine 
during the first 24 h after treatment, with more than 90 % of the compound being excreted at 96 h.  
 
After single oral administration in rodents, ACE is extensively metabolised, with 50-70 % of the dose 
being excreted as metabolites in both urine and faeces. After repeated administration, metabolites 
account for more than 90 % of the dose (Greece, 2001). The main metabolic pathway in rats is the 
demethylation to IM-2-1 (N1-[(6-chloro-3-pyridyl) methyl]-N2-cyanoacetamidine). This metabolite is 
further transformed to IC-O (6-chloronicotinic acid), with the release of IS-2-1 (N-cyanoacetamidine 
derivative) after cleavage from the side-chains (see Fig. 1). In lactating goats, less than 1 % of the 
radioactivity of the administered ACE was detected in milk, with the predominant residue being the 
IM 2-1 metabolite (JMPR, 2005). 
 
 
 
Figure 1:   Proposed metabolic pathways of ACE (NI-25, parent compound) in rats (for more details 
see  Joint  FAO-WHO  meeting  on  Pesticide  residues  in  food  -  Evaluations  2011; 
http://apps.who.int/iris/bitstream/10665/75147/1/9789241665278_eng.pdf) 
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Imidacloprid 
 
IMI is rapidly (Cmax was reached at 1-4 h) and almost completely absorbed after oral administration of 
1 or 20 mg/kg bw in rats and then widely distributed in the body to all tissues with the exception of the 
central nervous system (CNS), fatty tissues and the mineral portion of bone following either oral or 
i.v. administration (Klein, 1987). Maximum  concentrations are reached in kidneys and liver. It is 
excreted  mainly  via  urine  (75 %).  By  contrast,  other  studies  have  found  both  IMI  and  some 
metabolites, including desnitro-IMI, in the brain after intra-peritoneal administration of a single dose 
of the parent compound to mice (Ford and Casida, 2006). 
After oral administration of single and repeated doses to rats IMI shows extensive metabolism, with 
metabolites accounting for about 78 % of the recovered radioactivity. Up to 90 % of the administered 
dose is metabolised in the liver through two pathways (WHO, 2001; USDA, Forest Service, 2005). In 
the  first  route,  IMI  undergoes  aerobic  nitro-reduction  by  either  the  microsomal  CYP450s  or  the 
cytosolic molybdo-flavoenzyme aldehyde oxidase (AOX) to yield nitrosimine (M07, IMI-NO) and 
amino-guanidine (M08, IMI-NH2) derivatives and desnitro-IMI (M-09, IMI-NH) (Dick et al., 2007; 
Swenson and Casida, 2013). Desnitro-IMI is further degraded by oxidative cleavage of the methylene 
bridge to imidazolidine, which is excreted in the urine, and 6-chloronicotinic acid that undergoes 
further metabolism via glutathione conjugation to form mercaptonicotinic acid and hippuric acid. In 
the second major pathway, IMI is metabolised by hydroxylation of the imidazolidine ring by CYP3A4 
to form 4-hydroxy and 5-hydroxy metabolites (M01 and M02, respectively). This goes on to form 
glucuronide conjugates, and dihydroxy IMI (M03). The hydroxylated compounds may lose water to 
form the olefin metabolite (M06). Differences in AOX expression and nitroreduction may result in 
species differences in toxicity and residue dissipation (Swenson and Casida, 2013). 
It is not known whether IMI can be converted to desnitro-IMI in the brain. However, this possibility 
might theoretically occur because the nitroreduction is primarily due to AOX (Swenson and Casida, 
2013) and AOX has been found in liver, lung, brain and spinal cord (Kurosaki et al., 1999). 
 
Figure 2:   Proposed metabolic pathways of imidacloprid in the lactating goat FAO (adapted from 
http://www.fao.org/ag/AGP/AGPP/Pesticid/JMPR/Download/2002_eva/IMIDA_EVjjb.pdf). Developmental neurotoxicity potential of acetamiprid and imidacloprid 
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Either ACE or IMI are cleaved to the same urinary metabolite (6-chloronicotinic acid) derived from 
the chloropyridinylmethyl moiety. The desnitro-IMI is more active on mammalian ʱ4β2 receptors than 
the  corresponding  insect  systems  and  more  toxic  to  mammals  than  the  parent  insecticide.  This 
metabolite shows high affinity to and/or agonist potency at the mammalian ʱ4β2 nAChR subtype 
comparable to or greater than that of nicotine (Tomizawa and Casida, 2003). Accordingly, the desnitro 
metabolites can be considered as bioactivation products (Ford and Casida, 2006).  
 
Penetration of IMI and ACE through blood brain barrier (BBB) 
 
The evaluation of the actual relevance of the findings of Kimura-Kuroda et al. (2012) is hampered by 
the paucity of data concerning nicotinoids and neonicotinoids permeability to the BBB in adulthood 
and during development. IMI was initially thought to be excluded from vertebrate brain (Rose, 2012). 
In  contrast, the  study  of  Kimura-Kuroda  et  al.  (2012)  mentions that  ACE  and  IMI  “readily  pass 
through the blood brain barrier”, a statement based on data from Ford and Casida (2006) who report 
that at doses of 10 mg/kg intraperitoneally administered to adult albino mice, IMI and ACE penetrate 
into the brain reaching maximum tissue levels of 6 µg/g (15 min after dosing) and 3 µg/g (240 min 
after dosing), respectively. Comparatively, 18 and 12 µg/g were observed for liver and 8 and 6 µg/L 
for plasma. However, no information is currently available on permeability to IMI and ACE of the 
immature BBB. Any penetration is expected to be greater than at adulthood, though ontogeny of 
permeability to non-protein compounds is more heterogeneous and may depend on the nature of the 
agent considered (Saunders et al., 1999). 
 
The mammal BBB and particularly its development are increasingly known (Ballabh et al., 2004; 
Liebner et al., 2012). The rates of development of the brain vary between human and laboratory 
animal species (Engelhardt, 2006, 2008) and the rat is not considered a good model for extrapolation 
to humans. There is insufficient data to estimate risks in the infant less than 4 months old (Webster, 
2009) owing to the lack of knowledge on the efficiency of the BBB at various ages as well as to 
allometric considerations, which affect comparative dosage estimates and require refinement based on 
surface area rather than on mass. Accordingly, there is a need for further research to establish to what 
degree IMI and ACE and their metabolites cross into the human brain and to  quantify any such 
capacity at different stages of the BBB development. 
 
Nicotine, which is mostly protonated at physiological pH, is known to cross the adult human and rat 
BBB to become concentrated in the brain (Matta et al., 2007; Cisternino et al., 2013). Recent data on 
adult rats have found that an organic cation transport system (pyrilamine-sensitive) mediates blood-to-
brain influx transport of nicotine at the BBB and this process is expected to play an important role in 
regulating nicotine-induced neural responses (Tega et al., 2013). In an in situ brain perfusion study 
using the micromolar concentrations found in the plasma, most (79 %) of the net transport of nicotine 
at the BBB was carrier-mediated by a proton-coupled antiporter that helps nicotine cross the BBB at a 
faster rate and to a greater extent than passive diffusion, which accounts for 21 % (Cisternino et al., 
2013). This antiporter also transports and is competitively inhibited by other secondary or tertiary 
amine CNS compounds (André et al., 2009). Since desnitro-IMI behaves as a nicotinoid rather than a 
neonicotinoid compound, this metabolite might use the same transport system to reach the brain. In 
fact, the desnitro metabolite enters the brain following direct intraperitoneal administration in mice 
(Chao and Casida, 1997). As for permeability of nicotine into the developing brain, it is known that 
nicotine reaches the foetus through placenta and is concentrated in foetal blood at levels 15 % higher 
than in maternal blood (Luck et al., 1985). Nicotine is also transferred to the maternal milk with a 
milk/serum ratio of 2.9 (Luck and Nau, 1984). The effects of prenatal nicotine exposure on foetal 
brain  have  been  extensively  documented  in  rat  models,  including  cell  loss  (in  forebrain  and 
cerebellum), up-regulation of nAChRs and consequent alterations also on catecholaminergic function 
(Slotkin, 1998). 
 
It  is  known  that  nicotine  can  interact  directly  with  nAChRs  on  brain  endothelial  cells.  In  both 
preclinical and clinical studies, nicotine produce BBB dysfunction through alterations in tight junction Developmental neurotoxicity potential of acetamiprid and imidacloprid 
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protein expression and conformation, increased glial activation, increased enzyme activation related to 
BBB cytoskeleton remodelling, and induction of neuroinflammatory pathways (Kousik et al., 2012). 
Preclinical studies using rodent models of acute and chronic nicotine exposure reported compromised 
BBB integrity. In vitro, nicotine produces a dose-dependent (0.1–100μM) decrease in transendothelial 
electrical resistance leading to increased BBB permeability, sufficient enough to produce a 60–150 % 
increased invasion of Escherichia coli across brain microvascular endothelial cells (Kousik et al., 
2012). It is important to establish whether exposure to neonicotinoids such as ACE and IMI could 
affect BBB permeability. 
Mode of action as insecticides 
Both nicotine and neonicotinoid insecticides bind to nicotinic acetylcholine receptors (nAChRs) and 
mimic the action of acetylcholine by opening the ion channels which allow the entry of Na
+ and Ca
2+ 
into  cells.  These  compounds  vary  in  their  affinity  for  different  nAChR  subtypes,  with  nicotine 
showing  selective  toxicity  for  vertebrates  whereas  neonicotinoids  are  highly  selective  for  insect 
nAChRs. The binding of neonicotinoids to insect nAChRs is virtually irreversible. 
 
Despite the common structural features, neonicotinoids and nicotine have different protonation states 
at physiological pH. The basic nitrogen of nicotine will become positively charged in neutral aqueous 
solution because it is protonated by water. This positive charge gives nicotine a strong affinity for 
mammalian nAChRs as occurs with the ammonium head of ACh, which is an essential requirement to 
interact with the nAChRs (Tomizawa and Casida, 2003). At the same time, the charge on nicotine 
lowers its effectiveness as an insecticide, because the insect BBB reduces free access of ions through 
the central nervous barrier (Rose, 2012). The BBB does not prevent nicotine poisoning in mammals as 
it is well known that it crosses the BBB (Cisternino et al., 2013). In addition nicotine can interact with 
mammalian nAChRs located in the peripheral nervous system and necessary for vital functions such as 
breathing. 
 
Neonicotinoids  have,  instead  of  an  easily  protonated  nitrogen,  the  nitro  or  cyano  or  equivalent 
electronegative  pharmacophore,  crucial  for  optimum  insecticide  potency.  The  electronegative 
pharmacophore is believed to associate with a cationic subsite (possibly lysine, arginine, or histidine) 
in the insect nAChR (Tomizawa and Casida, 2003, 2005). The low mammalian toxicity of IMI and 
ACE can be explained in large part by the lack of a charged nitrogen atom at physiological pH. These 
compounds  show  weak  affinity  for  mammalian  nAChRs  but  strong  affinity  for  insect  nAChRs. 
Furthermore, the uncharged molecules can penetrate the insect BBB, while there is controversy about 
their ability to cross the mature human BBB. However, desnitro-IMI, which is formed in mammals 
during metabolism as well as in environmental breakdown, does have a charged nitrogen,  and is 
therefore similar to nicotine, and shows high affinity for mammalian nAChRs. For this reason it is 
considered as a nicotinoid rather than a neonicotinoid compound (Tomizawa and Casida, 2005). 
 
 
2.  Role of nicotinic acetylcholine receptors in acetamiprid and imidacloprid toxicity  
 
Receptors & mode of action 
The nAChRs are fast ionotropic receptors that form ligand-gated ion channels with unique localisation 
in pre-, post-, and extrasynaptic membranes. They are found in the CNS neurones of insects and in 
both the central and peripheral nervous systems of mammals as well as in neuromuscular junctions.  
 
In the cell membrane nAChRs are made up of a combination of five subunits (ʱ, ß, ʴ, γ and ξ) 
arranged symmetrically around a central pore. Each subunit comprises four transmembrane domains 
with both the N- and C-terminus located extracellularly. The signature cysteine loop is located in the 
N-terminal domain of the receptor. The assembly of differing combinations of subunits results in a 
large number of different receptors. Thus, the diversity of nAChR subunits is a major determinant of Developmental neurotoxicity potential of acetamiprid and imidacloprid 
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the specialised properties and functions of the mature receptors. The neuronal nAChR subtypes are 
various homomeric or heteromeric combinations of twelve different subunits: ʱ2 through ʱ10 and β2 
through β4. The expressed amounts of the various subtypes vary in different parts of the nervous 
system.  The  major  population  of  vertebrate  brain  nAChRs  appears  to  be  ʱ4ß2  and  ʱ7  subtypes 
(insensitive and sensitive to ʱ-bungarotoxin, respectively). It is known that ʱ7, ʱ8 and ʱ9 subunits are 
blocked by ʱ-bungarotoxin, while ʱ2 to ʱ6 and ß2 to ß4 are resistant to ʱ-bungarotoxin (Courjaret and 
Lapied, 2001). 
 
Ion-channel receptors reside in a constant equilibrium between open and closed states. Therefore, 
these  receptors  are  responsive  to  external  compounds  acting  as  activators  (agonists),  inhibitors 
(antagonists), or co-modulators of agonist/antagonist actions. When an agonist binds to the site, all 
present subunits undergo a conformational change and the channel (pore) is opened, promoting the 
influx of extra cellular sodium and efflux of intracellular potassium to disrupt the equilibrium status of 
the  membrane  potential  (Tomizawa  and  Casida,  2003).  Activation  of  nAChRs  causes  nervous 
stimulation  but  high  and  prolonged  levels  of  activation  lead  to  blockage  of  the  receptors 
(desensitisation). Total blocking of muscular-type receptors causes paralysis and death. 
 
Activation  of  nAChRs  often  results  in  increased  intracellular  free  Ca
2+  levels  through  the  direct 
passage of extracellular Ca
2+ across the receptor channels in neurons, in addition to Na
+ and K
+. The 
raised cytoplasmic calcium levels trigger a series of calcium-dependent intracellular processes. Among 
the different nAChR subtypes in the brain, the homomeric ʱ7 subtype exhibits higher permeability to 
Ca
2+ than the other ligand-gated ion channels permeable to this divalent cation, such as the NMDA (N-
methyl-D-aspartate)  receptor  (Takarada  et  al.,  2012).  This  receptor  subtype  is  also  known  to 
desensitise rapidly (Wu et al., 2011).  
 
The  functional  diversity  of  nAChRs  allows  channels  to  take  part  in  two  major  types  of 
neurotransmission. Classical synaptic transmission (wiring transmission) involves the release of high 
concentrations  of  neurotransmitter,  acting  on  immediately  postsynaptic  neighbouring  receptors. 
Binding  of  acetylcholine  to  these  receptors  is  a  key  step  in  the  physiology  of  nerve  to  nerve 
communication at the post-synaptic membrane where they give rise to trans-membrane currents and 
excitatory post-synaptic potentials. In contrast, paracrine transmission (volume transmission) involves 
neurotransmitters released by synaptic boutons, which then diffuse through the extracellular medium 
until they reach their receptors, which may be distant (Albuquerque, 2009). Agonists also bind to 
presynaptic sites where they cause neurotransmitters of other types to be released (Wonnacott, 1997). 
 
During brain development the toxicity depends on the window of the exposure due to the different 
stage  of  cell  differentiation/maturation.  Regarding  the  ʱ7  nAChR  subtype,  two  features  of  this 
homomeric receptor have to be taken into account from a toxicological perspective. First, the high 
levels of expression during brain development as compared to adults in both humans (Falk et al. 2002) 
and rodents (Zhang et al. 1998; Tribollet et al. 2004) support the important role of nAChRs for the 
development of the CNS and are indicative of a potential vulnerability of developing mammals to 
early neonicotinoid exposures. Secondly, the occurrence of ʱ7 nAChR in non-cholinergic neurons and 
in non-neuronal cells, e.g. astrocytes, microglia, T-lymphocytes and endothelial cells (Wu et al., 2011; 
Olofsson  et  al.  2012;  Taly  and  Charon,  2012)  suggests  that  target-cell  populations  of  the 
neonicotinoids  may  also  include  those  of  the  immune  system  and/or  those  that  mediate 
neuroinflammatory mechanisms, and angiogenesis.  
 
Interspecies differences in affinity for nAChRs 
 
Vertebrates and insects have structural differences in nAChRs, both in the subunit composition and in 
the structure  of  the  receptors themselves.  Both these  may  affect  the  receptor  binding  capacity  of 
specific  molecules.  Structural  variations  between  the  insect  and  mammalian  nAChRs  produce 
quantitative  differences  in  the  binding  affinity  of  the  neonicotinoids  to  these  receptors.  Most 
neonicotinoids show high affinity for insect nAChRs but low affinity for mammalian receptors. This 
in turn confers the notably greater selective toxicity towards insects compared to mammals (US-EPA, Developmental neurotoxicity potential of acetamiprid and imidacloprid 
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2012). However, not only affinity for receptors but also efficacy contributes to the insecticidal activity 
of neonicotinoids (Nishiwaki et al., 2003, Ihara et al., 2004). Efficacy describes the way that agonists 
vary in the response they produce when they occupy the same number of receptors. High efficacy 
agonists may produce their maximal response even while occupying a relatively low proportion of the 
total receptor population. Lower efficacy agonists do not activate receptors to the same degree and 
may not be able to produce the maximal response 
(http://www.tocris.com/pharmacologicalGlossary.php). In this regard, IMI is a high affinity but a low 
efficacy agonist of the human ʱ4ß2 receptor (Li et al., 2011). 
 
Each receptor subtype has distinct electrophysiological and pharmacological properties; for instance, 
the  ʱ4ß2-containing  nAChRs  have  the  highest  nicotine-binding  affinity  in  mammalian  cells, 
representing more than 90 % of the high affinity nicotine binding sites in mammalian adult brain. 
 
Neonicotinoids have little or no effect on the vertebrate peripheral neuronal nAChR subtype and on 
some  central  nAChR  subtypes,  including  ʱ4ß2  and  ʱ7  (Tomizawa  and  Casida,  2003).  Binding 
experiments  have  shown  that  IMI  and  ACE  have  low  to  moderate  potency  at  the  ʱ3  and  ʱ4ß2 
receptors  and  are  essentially  inactive  at  the  ʱ1  and  ʱ7  receptors  (Tomizawa  and  Casida,  1999). 
However, more recent studies have shown that IMI is significantly weaker compared to acetylcholine 
at activating chicken ʱ7 receptors and is essentially inactive at chicken ʱ4ß2 receptors (Li et al., 2011). 
From the Schild plot analysis
6, Li et al. (2011) estimated that the affinity of IMI f or the human ʱ4ß2 
receptor expressed in HEK (human embryonic kidney) cells is 18 µM. 
 
As  regards  the  specificity  of  nicotine  ACE,  IMI  and  some  IMI  metabolites  for  vertebrate  ʱ4β2 
nAChRs, the following IC50 (nM) have been reported (Tomizawa and Casida, 2005): 
 
 
Table 2:   Comparative  IC50  (nM)  of  nicotine,  acetamiprid,  imidacloprid  and  metabolites  for  the 
ʱ4β2 nAChRs 
 
Compound  Vertebrate  Insect 
Nicotine  7  4000 
ACE  700  8.3 
IMI  2600  4.6 
1. IMI-NH (desnitro IMI, M09)  8.2  1530 
2. IMI-NNO (nitrosimine metabolite, M07)  850  n.a. 
3. IMI-NH2 (amio-guanidine, M08)  42  n.a. 
4. IMI-olefin (M06)  1700  n.a. 
         n.a.: not available 
 
Minor structural changes of neonicotinoids may confer differential selectivity for different nAChR 
subtypes. These include those that occur in the metabolic pathways of the IMI parent compound 
within different mammal tissues, including brain (Ford and Casida, 2006). In particular, the desnitro 
IMI metabolite has affinity levels comparable to nicotine for the ʱ4 2 receptor, thus much higher than 
IMI  (Chao  and  Casida,  1997; Tomizawa  and  Casida,  1999  and  2002),  as  well  as for  ʱ1  and  ʱ3 
receptors  (Tomizawa  and  Casida,  1999).  In  ex-vivo  binding  studies  in  mouse  brain  membranes, 
desnitro IMI is a competitive inhibitor of nicotine binding (Chao and Casida, 1997). Another example 
of the spectrum of the effects of these "minor" structural changes of the IMI molecule that confer 
differential selectivity to nAChR has been reported with nitromethylene IMI analogues. Although 
these molecules are not IMI metabolites, their affinity for ʱ7 receptor subtype is higher than that of 
nicotine and IMI (Tomizawa and Casida, 1999).  
                                                       
6  The Schild plot is a pharmacological method of receptor classification. To construct a Schild plot, the dose-effect curve for 
an agonist is determined in the presence of various concentrations of a competitive antagonist. Developmental neurotoxicity potential of acetamiprid and imidacloprid 
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In experiments on mouse fibroblast M10 cells (stably expressing ʱ4β2 receptors) after 3 day exposure 
to IMI, nAChR binding was up-regulated by five- to eightfold. In contrast, the desnitro-IMI metabolite 
led to up-regulation by eightfold. Data on potency for in vitro nAChR up-regulation indicated that 
binding to the ʱ4β2 receptor initiates the up-regulation (Tomizawa and Casida, 2000). 
 
 
Physiological role of nAChRs during brain development 
 
Neurogenesis appears to be controlled by ionotropic signal inputs mediated by nicotinic cholinergic, 
GABAergic and glutamatergic systems in developing brains. Thus, the nAChRs play a key role in 
mammalian brain development and function (Role and Berg, 1996). The developmental role of these 
receptors in mammal brain is extensively understood, especially for presynaptic modulation of CNS 
synapses (Sher et al., 2004). Here, nAChRs play a role in formation of rudimentary neural and sensory 
circuits, neuronal pathfinding and neuronal survival during the early prenatal period (Dwyer et al. 
2009). 
 
The nAChRs are expressed in several brain structures such as cerebellum, hippocampus, entorhinal 
cortex, basal ganglia and thalamus (Court et al., 2000). The ʱ7 nAChR subtype is believed to be 
involved  in  the  regulation  of  neuronal  growth,  differentiation,  synapse  formation  and  synaptic 
plasticity during the development of the human brain (Falk et al., 2002). The ʱ7 receptors, which 
mediate the effects  of developmental  neurotoxicants,  increase  glutamate release  onto  postsynaptic 
NMDA receptors (Mao et al., 2007). Overactivation of ʱ7 nAChRs during development results in 
neuronal cell death, whereas stimulation in adult animals is neuroprotective (Laudenbach et al., 2002) 
In the murine hippocampal dentate gyrus, ʱ7 subunit appears to be essential for normal survival, 
maturation and integration of adult-born neurons (Campbell et al. 2010).  
 
Moreover,  high  levels  of  ʱ4  subunit  expression  in  human  foetal  brain  are  consistent  with  the 
hypothesis of a morphogenic role of nAChRs during the early CNS development (Agulhon et al., 
1998). Functional ʱ4β2 nAChRs are constitutively expressed in undifferentiated neural progenitor 
cells from foetal mouse neocortex where they play a pivotal dual role in the proliferation toward self-
replication  and  the  commitment/differentiation  into  particular  progeny  lineages  during  brain 
development (Takarada et al., 2012).  
 
Disruption of cholinergic innervation during early postnatal development (e.g. neonatal lesions to 
basal  forebrain  cholinergic  afferents  in  rats)  results  in  delayed  cortical  neuronal  development, 
permanent changes in cortical cytoarchitecture, and altered cognitive function (reviewed in Hohmann 
and Berger-Sweeney, 1998). Furthermore, the impaired cholinergic transmission during ontogenesis 
may  be  associated  with  some  developmental  brain  disorders  such  as  autism,  Rett  syndrome  and 
attention deficit and hyperactivity disorder (ADHD), with muscarinic receptors playing also a key role 
in  cortical  morphogenesis  (Hohmann  and  Berger-Sweeney,  1998;  Court  et  al.,  1997,  2000). 
Nevertheless,  the  administration  of  nicotine  and  nicotine  agonists  has  shown  to  reduce  ADHD 
symptoms severity (reviewed in Gizer et al., 2009). On the other hand, genes encoding nAChR ʱ4 
(CHRNA4) and ʱ7 (CHRNA7) subunits may represent candidate genes for autism, Rett syndrome and 
ADHD, although the evidence is limited (Gizer et al., 2009; Yasui et al., 2011; Williams et al., 2012).  
 
 
3.  Comparative Morphology and Development of Rat and Human Cerebellar Cortex  
 
The paper under consideration (Kimura-Kuroda et al., 2012) used cultured rat neonatal cerebellar 
granule cells exposed to ACE and IMI and this  Opinion addresses potential DNT of these active 
substances  in  humans.  Thus,  this  section  provides  a  comparative  study  of  morphology  and 
development between rat and human cerebellar cortex. 
 Developmental neurotoxicity potential of acetamiprid and imidacloprid 
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The cerebellum is composed of three major histological subdivisions: the cortex, the underlying white 
matter  and  the  deep  cerebellar  nuclei  (Biran  et  al.,  2012).  The  basic  histological  layering  of  the 
cerebellar cortex is similar in rodents and primates and consists of five different types of neurons 
organised in three distinct cellular layers (see Fig. 3 and 4):  
 
  Molecular layer, the most superficial one, is composed of stellate and basket cells, two types of 
inhibitory interneurons that form synapses onto Purkinje cell dendrites. The axons of the granular 
cells penetrate to the molecular layer where they divide in a T-shaped manner to form parallel 
fibers that make excitatory contacts with dendrites of Purkinje cells. 
  Purkinje cells layer (also referred to as the piriform layer). This is a thin row of cell bodies of 
Purkinje cells and climbing fiber terminals, which make excitatory synapses with the dendritic tree 
of a Purkinje cell. Purkinje cell axons penetrate the granular cell layer and most of them terminate 
in deep cerebella nuclei, where they exert an inhibitory function. 
  Granular layer, the most internal one, is comprised by the small and thickly populated granular 
cells, inhibitory interneurons (Golgi type II cells) and excitatory mossy fibers that synapse onto 
granule cell dendrites and stimulate them. Cerebellar granule cells send parallel fibers up through 
the Purkinje layer into the molecular layer where they branch out and spread through Purkinje cell 
dendritic  arbors.  These  parallel  fibers  form  thousands  of  excitatory  granule  cell-Purkinje  cell 
synapses onto the intermediate and distal dendrites of Purkinje cells. 
 
All of these cell types, with the exception of the granule cells, use the inhibitory neurotransmitter 
GABA. Granule cells use glutamate as their neurotransmitter, and therefore exert excitatory effects on 
their targets. Both stellate and basket cells form GABAergic synapses onto Purkinje cell dendrites. 
The Purkinje cell is the only neuronal type that has an axon that leaves the cerebellar cortex. There are 
only two types of axons that enter the cerebellum, mossy fibers and climbing fibers. Climbing fibers 
arise only from the inferior olivary nucleus, while mossy fibers comprise all of the other cerebellar 
inputs. Both of these fiber types release excitatory neurotransmitter, glutamate in the case of the mossy 
fibers and aspartate in the case of climbing fibers (Swenson, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3:   Histological sections of the cerebellar cortex layers. 
Left:  human  cerebellum  (Department  of  Experimental  Biology,  University  of  Jaen,  Spain; 
http://virtual.ujaen.es/atlas/cerebelo/cerebelo10x.htm).  
Right: rat cerebellum (http://biofinity.org/images/Rat%20Cerebellum%20Micrograph.jpg) 
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Figure 4:   Schematic representation of the cerebellar cortex layers (Atlas Catalog.Veterinary 
Neurohistology. Central Nervous system 
http://vanat.cvm.umn.edu/neurHistAtls/cataPages/cataCNS.html).  
 
During  cerebellum  ontogenesis,  in  contrast  to  other  regions  of  the  CNS,  cerebellar  neurons  are 
generated in two germinative neuroepithelia in two waves of proliferation and migration processes that 
occur in similar order but at different rates in rodents and primates (Biran et al., 2012): 
 
  The first neurons to be generated are the deep nuclear neurons and all the Purkinje cells that 
migrate  immediately  thereafter  to  the  cerebellar  plate.  In  parallel,  the  first  granular  cell 
precursors are generated and then migrate tangentially to cover the superficial zone of the 
cerebellar plate forming the extragranular layer.  
 
  During postnatal life, the second wave of proliferation occurs in the extragranular layer. The 
secondary germinal zone gives rise to the granular cells which migrate radially inward to their 
final destination in the internal granular layer. In the molecular layer, the onset of synaptic 
inputs of the axons of the granular cells (parallel fibers) is concomitant with the onset of the 
final postsynaptic dendritogenesis of the Purkinje cells. In the rat, although the extension of 
the lateral domain of the dendritic tree of the Purkinje cells is achieved at postnatal day 15 
(PND 15), its final adult size is reached at PND 30 (Altman and Bayer, 1985). In humans, the 
adult number of narrow, leaflike gyri of the cerebellar cortex (referred to as folia or cerebellar 
laminae) is achieved around two months postnatally (Loeser et al., 1972) and the extragranular 
layer disappears around the 7th postnatal month (Sidman and Rakic, 1973). Developmental neurotoxicity potential of acetamiprid and imidacloprid 
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Figure 5:   Comparison  of  timing  of  development  of  the  Purkinje  cells  (PC,  in  blue  colour)  and 
cerebellar granular cells (CGC, in green colour) in the cerebellar cortex in rat and human. EGL: 
external granular layer; Embryonic day (ED), postnatal day (PND), gestational weeks (gw), postnatal 
months (pnm) (adapted from Biran et al., 2012). Vertical dotted red lines indicate the time interval that 
elapses between when CGCs were taken from neonatal rats in the Kimura-Kuroda et al. study (PND 1) 
and the end of the in vitro culture time (14 additional days). At this time, CGCs are already mature. 
 
 
 
4.  Review of the paper by Kimura-Kuroda et al. (2012) 
 
4.1.  Background and Scope 
 
Studies of four main types were quoted by the authors on effects of neonicotinoids on the vertebrate 
nervous system:  
i)  in vitro data, ranging from nAChR modulation in rat PC12
7 cells to whole-cell patch-clamp 
recording in stellate cells of mouse cochlear nucleus after IMI exposure at doses of  ≥10 µM 
(Nagata et al. 1998; Bal et al. 2010); 
ii)  in vivo data from intracranial (striatal) neonicotinoids exposure and subcutaneous repeated 
injections of thiamethoxam in adult rats (de Oliveira et al. 2010); 
iii)  in vivo data from developmental exposure studies where a single intraperitoneal injection of 
337 mg/kg bw (75 % LD50) was administered to rats on gestational day 9 (Abou-Donia et al. 
2008); 
iv)  in vitro direct activation of the human ʱ4ß2 receptor (measured by patch clamp techniques) 
after IMI treatment (Li et al., 2011).  
 
                                                       
7  PC12 is a cell line derived from a pheochromocytoma of the rat adrenal medulla that can be used as a model system for 
neuronal differentiation. Developmental neurotoxicity potential of acetamiprid and imidacloprid 
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Based on these  studies, the authors investigated potential developmental neurotoxic effects of  the 
widely-used neonicotinoid insecticides IMI and ACE using an in vitro system of neuronal cells, the 
cerebellar granule cells (CGCs) of neonatal rats. Nicotine was used as a “positive control” because of 
its known effects on mammalian nAChRs.  
 
 
4.2.  Methodology 
 
Experimental design  
 
The in vitro system consisted of primary cell cultures of rat CGCs isolated from PND 1 pups that were 
cultured for 14 days in vitro (DIV). The cell proportion was CGCs (90 %), Purkinje cells (1 %) and 
astrocytes (5 %). In this system, CGCs expressed several types of nAChR (ʱ3, ʱ4 and ʱ7), which were 
confirmed by measuring mRNA expression of these receptor subunits at 14-16 DIV.  
 
The  cultures  were  exposed  to  0.5  to  100  µM  solutions  of  the  test  substances  using  continuous 
perfusion by means of a peristaltic pump for up to 10 minutes. A subset of perfusions was followed up 
by exposure to 100 mM KCl 500 seconds thereafter in an attempt to stimulate the neurons. Another 
subset  included  prior  application  of  selective  antagonists  for  different  types  of  nAChRs  (ʱ-
bungarotoxin for ʱ7 receptors, dihydro-β-erythroidine for ʱ4β2 receptors and mecamylamine, as a 
relatively  selective  antagonist  for  ʱ3β4  receptors).  The  parameter  studied  was  the  Ca
2+  influx 
measured using a Fluo-4-based assay and the related excitatory patterns in cell cultures and single 
cells. The peak intracellular concentrations of Ca
2+ and the proportion of the excited neurons were 
measured. The influence of prior administration of the antagonists was also assessed. 
 
 
4.3.  Interpretation of the results by the authors 
 
Kimura-Kuroda et al. (2012) suggest that IMI and ACE, similarly to nicotine, exert excitatory effects 
on  nAChRs  of  CGCs  in  culture  at  low  concentrations  (starting  from  1µM)  and  therefore  may 
adversely affect the developing human brain.  
 
The authors considered the readout of the Fluo-4-based assay as an „index of neuronal physiological 
activity‟.  Application  of  ACE,  IMI  or  nicotine  led  to  a  marked  transient  increase  in  Fluo-4 
fluorescence intensity that was interpreted as a transient increase in calcium influx. This intracellular 
Ca
2+ mobilisation in CGCs revealed that ACE and IMI have agonist activity on mammalian nAChR 
since a characteristic excitatory pattern was induced. This effect appeared to conform to an all-or-none 
response pattern, as concentrations of 1, 10 and 100 µM of the individual test substances all essentially 
elicited the same magnitude of response (peak fluorescence), while doses of 0.5 µM did not have any 
detectable effect.  
 
4.4.  Comments of the PPR Panel 
 
Since cerebellar development takes place much later than that of other brain structures, and as it 
continues postnatally in both humans and rats, primary CGC culture is a suitable and widely used 
system for in vitro DNT studies (Bal-Price et al., 2010a).  
 
Although a number of mechanistic aspects remain to be clarified, the data clearly show consistent and 
treatment-related  effects  and  a  no-effect  concentration  was  identified  for  both  neonicotinoid 
compounds. However, the toxicological relevance of these observations remains to be defined as the 
applied  assay  covers  only  one  narrow  aspect  of  neuronal  function  and/or  development.  The 
information provided by the study cannot be directly extrapolated to predict the outcome of in vivo 
exposures in adult or developing humans or other mammals.  
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Experimental design 
 
In the study, exposure to IMI and ACE was performed acutely at 14 DIV. At this time, the culture of 
CGCs is expected to have already reached advanced maturation since proliferation, migration and 
some stages of differentiation should have already taken place (Bal-Price et al., 2010b). Therefore, the 
results  relate  to  mature  neurons  (adult  neurotoxicity  rather  than  to  developmental  neurotoxicity). 
Moreover,  additional  DNT  specific  endpoints  should  have  been  studied  to  determine  if  key 
developmental  processes,  such  as  neuronal  migration,  differentiation  (e.g.  neurite  outgrowth, 
synaptogenesis), glial proliferation and maturation, might be affected by the exposure to IMI and ACE 
at non-cytotoxic concentrations during early stages of cell culture, prior to the time when neurons are 
fully differentiated (approximately 10 DIV). 
 
 
Decreased content of glial cells 
 
In the paper under study, the culture medium was replaced at 2 DIV by serum-free synthetic medium 
to prevent growth of astrocytes. As a result, the culture contained around 5 % of glial fibrillary acidic 
protein (GFAP) positive cells (astrocytes), which is less than in the culture with serum, where the glial 
proportion is around 18 % (~13 % astrocytes and ~5 % microglia; Hogberg, 2010). In the Kimura-
Kuroda paper there is no data on the content of microglia and oligodendroglial cells. The presence of 
glia is important as these cells, especially astrocytes, protect neurons against toxic insults. The content 
of glia differs in different brain structures (Azevedo et al., 2009). Neurotoxicity is generally lower in 
mixed (neuronal/glial) cultures which have greater numbers of astrocytes. In addition, the presence of 
astrocytes is important for cell-cell interaction as these cells secrete factors that modulate synaptic 
transmission and enhance the formation of neuronal interconnections (Hatton, 2002). Overall, the PPR 
Panel considers that in vitro systems with a low content of glial cells have less direct relevance to the 
in vivo situation.  
 
 
CGCs culture medium without KCl 
 
A protocol with KCl free medium was previously used by Kimura-Kuroda et al. (2002) for culture of 
cerebellar Purkinje cells in mice. However, it is not known whether it is optimal for CGCs as it could 
affect  the  process  of  neuronal  maturation  as  well  as  the  response  of  the  CGCs  to  the  applied 
treatments. 
 
KCl causes membrane depolarisation due to the increase in the equilibrium potential of potassium and, 
thus,  is  widely  used  for  studying  electrical  activity-dependent  changes  in  neurons,  muscle,  and 
endocrine cells. However, the medium used for the CGCs culture did not contain KCl solution. The 
classical method for measuring activity-dependent responses in granule neurons in culture was based 
on a method that uses membrane-depolarising concentrations of extracellular KCl. KCl should be 
present in the medium of CGCs at high concentration (on average 25 mM) (Cold Spring Harbor 
Protocols: Culture of cerebellar granule cells, 2008). This high concentration is critical as membrane 
depolarisation-induced transmembrane Ca
2+ flux is essential for the maintenance of the granule cells. 
It  mimics  the  influence  of  the  in  vivo  physiological  stimulation  through  excitatory  amino  acid 
receptors including NMDA receptors, involving Ca
2+ entry and the activation of Ca
2+/calmodulin-
dependent protein kinase (Yan et al., 1984; Gallo et al., 1987; Sée et al., 2001; Sato et al., 2005; 
Suzuki et al., 2005).  
 
Additionally, calcium-dependent signalling pathways regulate the gene expression profile of CGCs 
(Kramer et al. 2003; Sato et al. 2005). An interesting example is the developmental switch that occurs 
in subunit composition for GABAA and NMDA neurotransmitter receptors as granule neurons mature 
(Watanabe et al., 1992; Farrant et al., 1994; Mathews et al., 1994). Upon hyperpolarisation, the ʱ6 
subunits  of  the  GABAA  receptor  and  the  NR2C  subunit  of  the  NMDA  receptor  are  up-regulated 
(Mellor et al., 1998; Suzuki et al., 2005; for review see Nakanishi and Okazawa, 2006). Developmental neurotoxicity potential of acetamiprid and imidacloprid 
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Developmental role of nAChR in brain 
 
Since IMI and ACE are nAChR agonists, it is important to characterise their effects well in the context 
of  developmental  neurotoxicity.  To  investigate  the  role  of  nAChRs  during  neuronal 
development/maturation under in vitro conditions it would be necessary first to conduct kinetic studies 
of nAChR expression to define at what developmental stage these receptors are expressed and to 
define what role they play in neuronal differentiation (e.g. using specific receptor antagonists).  
 
 
Evaluation of the applied methodology 
 
The imaging of calcium influx into cells is a common and useful technique for measuring calcium 
signals in functional neurons in culture and provides a useful indirect measure of action-potential 
generation within individual neurons. The key advantage of the technique is that it allows monitoring 
the activity of a large population of neurons with single-cell resolution.  
 
Calcium  imaging  techniques  take  advantage  of  calcium  indicator  dyes,  which  are  BAPTA
8-based 
organic molecules that change their spectral properties  in response to the binding of Ca
2+  ions. 
Kimura-Kuroda et al. (2012) measured the calcium (Ca
2+) influx into cells by using the Ca
2+-sensitive 
fluorescent dye Fluo-4. This increases calcium-dependent fluorescence excitation at 488 nm by argon 
ion laser and gives higher signal levels and ease of use for confocal microscopy without requiring the 
use of a background quencher dye. The method is widely used and highly sensitive. The choice of 
Fluo-4 was considered by the PPR Panel to be appropriate and relevant as it was expected to allow 
measurement of the response of the cells to further treatments after the application of neonicotinoids. 
 
 
 
 
 
 
 
Figure 6:   Fluo-4 chemical structure (A) and absorption and fluorescence emission spectra (B). 
 
 
In the Kimura-Kuroda et al. study, CGC cultures were preloaded with Fluo-4 acetoxymethyl ester 
(Fluo-4 AM, the precursor of Fluo-4) prior to treatment with different doses of IMI, ACE and nicotine. 
This precursor is generally expected to easily penetrate the cell membrane. Once within the cell, it is 
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assumed to be degraded by esterases yielding Fluo-4, whose fluorescence increases dramatically upon 
binding of divalent cations (e.g., Ca
2+). 
 
Both nicotine and the two neonicotinoids studied produced a significant transient increase in Fluo-4-
dependent fluorescence, which may be interpreted as an increase in Ca
2+ influx. However, no plausible 
explanation was provided for the mechanism(s) underlying this apparently dose-independent all-or-
none response. It is not clear to which extent various difficulties that might occur when working with 
indicator dyes have been taken into account within the study, e.g. leakage of dye from the cells (which 
might lead to an attenuated response after prolonged cellular perfusion) or compartmentalisation of the 
dye.  
 
AChR antagonist assays 
 
Pretreatment/concomitant  treatment  of  cell  cultures  with  different  antagonists  of  nAChRs  either 
suppressed  or  prevented  the  nicotine-,  IMI-  or  ACE-dependent  transient  increase  in  Fluo-4 
fluorescence, suggesting that Ca
2+ influx was due to activation of nAChRs. Two antagonists believed 
to be selective for a particular receptor subtype were used: ʱ-bungarotoxin for the ʱ7 subtype and 
dihydro-ß-erythroidine  (DHbE)  for  ʱ4ß2  and  ʱ3ß4  subtypes.  However,  results  did  not  allow 
specification of the predominant receptor subtype responsible for the observed effect. The IMI-, ACE- 
and nicotine-induced Ca
2+ influxes in neurons were completely blocked by the homomeric antagonist 
ʱ-bungarotoxin,  indicating  that  the  effect  was  mediated  by  ʱ7  receptor  subtype.  However,  the 
heteromeric nAChR antagonist DHbE also blocked the response. The involvement of ʱ7 receptor in 
mediating  IMI  and  ACE  effects  could  be  important  because  they  are  particularly  abundant  in 
developing brains of rodents (Zhang et al, 1998; Tribollet et al., 2004) and humans (Falk et al., 2002) 
from very early phases of prenatal development (Dwyer et al. 2009). Presynaptic ʱ7 receptors are 
responsible for generating very fast calcium currents and, when they do so, causing neurotransmitters 
release (Dani 2001; Rousseau et al., 2005), but in other cases non-ʱ7 subtypes are also involved 
(Nagumo et al., 2011). 
 
 
Extracellular KCl challenge 
 
Kimura-Kuroda et al. (2012) also tested whether treatment with either nicotine, IMI or ACE might 
affect the response of cells to an increase in extracellular KCl (100 mM). KCl is expected to cause 
membrane  depolarisation  and  thus  an  increase  in  calcium  influx  via  voltage-dependent  calcium 
channels. Lack of response to KCl (100 mM) was observed after application of ACE or IMI (even 
after washing the compounds out), indicating that neurons were in a non-conducting, inactivated state. 
This is an important demonstration of functional damage caused by these compounds to the neurons, 
which might not be able to respond correctly to the physiological stimulus. It is noted, however, that 
the time frames between application of the individual test substances and the KCl challenge appeared 
to differ between the experiments with different test substance concentrations. Moreover, a normal 
response to KCl was observed for nicotine at the highest dose tested (100 µM) eliciting a somewhat 
stronger calcium influx than IMI and ACE. Neither 10 nor 1 µM produced this effect. This finding 
was not properly discussed by the authors but it deserves a scientific explanation. 
 
Additionally, the fact that CGCs were cultured for 14 DIV without KCl in the medium could affect the 
process of neuronal maturation as well as the response of the neurons to KCl treatment. 
 
 
Lack of biotransformation under in vitro conditions  
 
The metabolic activity of the cultured neuronal and glial cells is low or absent (Bal-Price 2010a), 
therefore it is important to know whether in vivo toxicity of IMI and ACE is mediated by metabolites, 
by the parent compound, or by both. The low (or the absence of) metabolism under in vitro conditions 
could affect and likely underestimate the interpretation of results obtained in cell culture studies. As Developmental neurotoxicity potential of acetamiprid and imidacloprid 
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has  been  mentioned  above,  the  desnitro  metabolite  of  IMI  exhibits  higher  affinity  for  vertebrate 
nAChR and causes higher acute toxicity. On the other hand all ACE metabolites are of lower toxicity 
than the parent compound (JMPR, 2005). 
 
 
Evaluation of IMI and ACE concentrations applied to the in vitro system  
 
The  PPR  Panel  cannot  rule  out  some  methodological  uncertainties  in  reporting  the  effective 
concentrations of nicotine, ACE and IMI. For instance: a) the volume of the medium surrounding the 
exposed cells is unknown; b) it is not clear whether the concentrations reported were measured in the 
pressure pipette, or whether they were the diluted ones collected after application (in this last case, a 
lower  concentration  than  the  ones  in the  pipette  would  be  expected);  c)  each  administration  was 
effected locally,  and  pressure  was applied to  a  syringe  whose tip  was  100  µm  from  the  neurons 
imaged; d) the stability of the compound in culture medium was not evaluated; e) the binding of ACE 
and IMI to plastic and culture medium was not determined so the free concentration of the compounds 
were not defined. 
 
 
Dose-response relationship 
 
Difficulties in interpreting the value of the paper under study for risk assessment, apart from the 
methodological uncertainties outlined above, stem from the claim that neonicotinoid concentrations 
showing  effects  in  the  in  vitro  assay  corresponded  to  dose  levels  much  lower  than  the  NOAEL 
determined in the regulatory in vivo tests (e.g., 50 times lower in the case of IMI). Accordingly, it is 
hard to interpret the reliability and usefulness of the study for risk assessment. The dose-response 
relationship, though often linear for active substances, may not always be so. There is some evidence 
that nonlinearity may be the case for ligands binding to the nAChRs, which exhibit an inverted U-
shaped dose-response curve (Matta et al., 2007). It is regrettable that a larger number of intermediate 
concentrations (e.g., between 0.5 and 1 µM) of IMI and ACE was not tested as this could have 
contributed to a more robust and comprehensive set of data. Such information would be valuable to 
find the limit concentration for the response in vitro and suggests that further research is warranted. 
 
 
Comparison of concentrations of actives used in vitro with reported human toxicity cases 
 
Three cases are reported in the published literature of acute ACE poisoning. After 120 min. from a 
subcutaneous administration of about 8 ml of a formulation containing 18 % of ACE, a 58 year-old 
male showed a concentration level of 2.39 µg/ml (10.7 µM), whereas a 74 year-old woman had a 
serum concentration of 59.83 µg/ml (268 µM) after ingestion of about 100 ml of a solution containing 
2 % of ACE (Imamura et al., 2010). The third case involved a 79-year-old man who showed a blood 
concentration of 21.1 µg/ml (94.7 µM) some time after the ingestion and was discharged from hospital 
without complication on the next day (Todani et al., 2008). 
 
In a prospective human case series, of 56 patients with acute self-poisoning due to a commercial IMI 
formulation,  who  had  been  admitted  to  a  hospital,  54  had  symptoms  such  as  nausea,  vomiting, 
headache, dizziness, abdominal pain, and diarrhoea during the hospital stay. These symptoms were 
largely self-resolving. The median Glasgow coma score
9 on presentation was 15 (IQR: 10–15). There 
were  no  deaths,  but  two  patients  developed  more  severe  symptoms  requiring  management  in  an 
intensive care unit. The median volume amount ingested was 15 mL (IQR 10–50 mL). Exposure was 
confirmed in 28 patients, with a median admission plasma concentration of 10.58 ng/L (0.047 nM); 
IQR: 3.84–15.58 ng/L and range: 0.02–51.25 ng/L (Mohamed et al., 2009). Owing to the time gap 
between  ingestion  and  blood  sampling,  these  concentrations  do  not  reflect  the  maximum  plasma 
                                                       
9  Glasgow  Coma  Scale (GCS)  is  a  neurological  scale that  aims  to  give  a  reliable and  objective  way  of  recording  the 
conscious state of a person. GCS values ranges from 3 (deep coma state) to 15 (normal). Developmental neurotoxicity potential of acetamiprid and imidacloprid 
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levels. As some patients were treated with atropine and oximes because of suspected organophosphate 
intoxication, the effects of IMI poisoning might have been enhanced. 
 
 
Comparison of concentrations of active substances used in vitro with in vivo animal studies 
 
It is useful to try to link the data in the Kimura-Kuroda et al. (2012) experiments with the extensive 
literature on nicotine to establish whether the doses administered are likely to be of pharmacological, 
physiological,  behavioural  or  toxicological  relevance.  The  rise  in  concentration  of  nicotine  in  a 
smoker‟s  blood  that  has  not  been  abstaining  is  maximal  just  after smoking  a  cigarette,  variously 
estimated as reaching a peak concentration of 10.9 ng/ml (0.067µM) (Patterson et al., 2003) or 25-50 
ng/ml corresponding to 0.154-0.307 µM (Benowitz et al., 1988). Plasma concentrations retrieved from 
rat plasma following injections to the femoral artery of 1 mg/kg of nicotine peaked at 0.0021 µM after 
10 minutes, falling to 0.0007 µM after 20 minutes (Sastry et al., 1995). In contrast, the range of 
concentrations of nicotine used by Kimura-Kuroda et al. (2012) was considerably greater, ranging 
from 1-100 µM.  
 
From the results of kinetic studies conducted with single doses of IMI in rats (Klein, 1987), the 
association  between  in  vivo  dose  levels  (mg/kg  bw)  and  the  plasma  concentrations  at  Tmax 
(approximately 1 h after dosing) was as follows: 
-  Rat: 1 mg/kg bw (oral) caused a Cmax plasma of 0.72 µg/ml, equivalent to 2.8 µM 
-  Rat: 20 mg/kg bw (oral) caused a Cmax plasma of 13 µg/ml, equivalent to 50 µM 
 
These results demonstrate approximate dose linearity. Taking into account these data, the estimated 
NOAEL for DNT reported for IMI (5.5 mg/kg bw, see section 5.3) would result in 15.4 µM, which 
falls within the dose range assayed by Kimura-Kuroda et al. (2012) that induced adverse effects on 
CGCs (1-100 µM). Thus, a clearly effective in vitro concentration corresponds to a dose level in vivo 
devoid of any neurotoxic effects in the available DNT studies. 
 
DNT effects are usually induced by low doses of environmental chemicals and chronic exposure. 
However, Kimura-Kuroda et al. (2012) focused only on the acute effects. Acute exposure per se might 
be relevant to developmental effects when it occurs at a critical phase in utero or during lactation. In 
addition,  it  would be  relevant  to  study  the  in  vitro  effects  induced by  lower  concentrations after 
repeated/prolonged exposure as the effect pattern may be different. 
 
Relevance of the rat in vitro results to the in vivo situation 
 
A crucial point is the exposure regimen used and its comparability to in vivo systemic exposures to 
IMI  and  ACE.  The  in  vitro  situation  may  differ  as  a  result  of  ADME  (absorption,  distribution, 
metabolism, excretion) differences in vivo, differences between species and among individuals of one 
species due to lifespan, gender, ill-health and other factors (Matta et al., 2007).  
 
The experiments recorded in the Kimura-Kuroda et al. (2012) study were performed on an exposed 
population of neurones treated with neonicotinoids that have direct access to the cell surfaces where 
the  nAChRs  are  available.  The  results  indicated  that  IMI  and  ACE  have  agonist  activity  on 
mammalian  nAChRs  at  a  concentration  of  1  µM,  which  is  much  lower  than  the  concentrations 
predicted from their binding affinities performed on isolated cell membrane fractions. For a better 
interpretation of this finding, there is a need to know how relevant the in vitro concentrations of IMI 
and ACE are to the concentrations that may reach the brain in vivo. It should also be considered that in 
vivo toxicity of IMI is triggered by both the parent compound and its active (toxic) metabolites. 
 
Additional studies are required to determine whether the results obtained by Kimura-Kuroda et al. 
(2012) are reproducible. Not only CGC culture but also other brain structures that express nAChRs 
(e.g. cortex and hippocampus) should be investigated. Experiments are also required to determine Developmental neurotoxicity potential of acetamiprid and imidacloprid 
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whether the observed effects are reversible. Interpreting the lack of response to 100 mM KCl would be 
helped by such studies. 
 
It is of note that a single analytical parameter was measured in the Kimura-Kuroda study, specifically 
changes in intracellular Fluo-4 fluorescence as an indicator of changes in intracellular calcium. In 
order to better relate the results of this study to the in vivo situation and to define a cellular response, 
parameters  other  than  intracellular  calcium  levels  should  be  tested.  Additional  positive  control 
experiments  using  other  nAChR  ligands  (particularly  acetylcholine)  and  further  negative  control 
experiments should be carried out. 
 
Overall, uncertainties limiting the ability to extrapolate from these results to human risk assessment 
arise from: a) knowledge gaps and limited value of animal models, and b) difficulties in identifying in 
vitro endpoints suitable for establishing regulatory reference values. The first ones include:  
 
  Species differences between rat and human. 
  Data gaps regarding permeability of the immature blood brain barrier to IMI and ACE. 
  The lack of knowledge of concentrations of IMI and ACE at the adult cerebellum in vivo that 
should be used for relevant concentration ranges for in vitro studies. In Kimura-Kuroda et al. 
(2012) experiments the free concentrations of ACE and IMI that reach the cells are unknown, and 
only nominal concentrations are available in vitro. 
  The role of metabolism regarding the toxicity of the metabolites on the developing brain. 
  The levels of partition of IMI and ACE into the foetal brain throughout development and any 
concentration/dilution effects in human breast milk following exposure of the mother. 
  The  rates  of  metabolism  and  excretion  in  adults  and  at  the  relevant  developmental  stages, 
including the role of maturation of the detoxifying organs such as the liver. 
  The incomplete investigation of toxicity at each developmental stage, and in particular the stage(s) 
of development at which the developing cerebellum is most vulnerable. 
  The  permanence  of  any  changes  and  the  extent  of  any  ability  of  the  developing  brain  to 
compensate the toxic effects by adaptation or defence mechanisms. 
 
Difficulties  in  identifying  in  vitro  endpoints  suitable  for  establishing  regulatory  reference  values 
include: 
  The simplicity of the CGCs cultures may not reflect the more complex in vivo situation.  
-  Susceptibility of CGCs may depend on the proportion of glial cells within the culture. 
-  The tested cells represent a small population of the brain cells and other CNS structures 
may be more sensitive.  
-  There is a lack of knowledge about the responses of the other structures of the CNS.  
  The lack of a clear linkage between the effects measured on intracellular free calcium, the neural 
responses and the neurodevelopmental outcomes of those responses. 
 
While the findings cannot be ignored, further research is definitely needed to establish to what extent 
measurements of in vitro neurotoxicity are relevant to human risk assessment. 
 
 
 
5.  The Guidelines for Developmental Neurotoxicity (DNT) Testing: Comments of the PPR 
Panel 
 
Developmental neurotoxicity (DNT) studies according to the OECD TG 426 or the corresponding 
USA  EPA  guideline  (USA  EPA,  1998)  are  designed  to  provide  information  on  the  potential 
functional, behavioural and morphological effects on the developing nervous system after in utero and 
early life exposure to chemical compounds. More recently, OECD has published the extended one-
generation reproductive toxicity study (TG 443) that also allows to assess the potential impact of Developmental neurotoxicity potential of acetamiprid and imidacloprid 
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chemical exposure on the developing nervous system (OECD, 2011). This new guideline is intended 
to evaluate all developing life stages, both prenatal and post-natal up to puberty, and the extended 
impact of developmental hits up to adulthood. Testing guideline 443 would cover in a detailed way 
specific  endpoints,  such  as  nervous  system  or  immune  function,  according  to  the  indications  by 
previous studies. However, systematic testing for DNT is not routinely required by most regulatory 
agencies  and  becomes  obligatory  only  if  it  has  been  triggered  by  the  observations  during  organ 
toxicity testing (Bal-Price et al., 2010 and 2011). 
 
As early as 1998, the US-EPA published the test guidelines OPPTS 8706300 on DNT. This was the 
basis  for further  development  of  the  OECD TG  426,  which  was endorsed  in  2007. The TG  426 
addressed  important  issues  and  incorporated  improvements  recommended  by  expert  consultation 
meetings held between 1996 and 2005. Both US-EPA and OECD guidelines are based entirely on in 
vivo studies in which the test substance is administered to rodents during gestation and lactation to 
cover  critical  pre-  and  postnatal  periods  of  nervous  system  development.  Then,  gross  functional, 
behavioural  and  neuroanatomical  abnormalities  are  assessed  during  postnatal  development  and 
adulthood (Figure  4).  These  assessments  encompass  physical  development,  behavioural  ontogeny, 
motor  activity,  motor  and  sensory  function,  learning  and  memory,  brain  morphometry  and 
neuropathology. However, for learning and memory assessment the guidelines methodology is flexible 
and its sensitivity varies, which may lead to some deficit in these domains and subtle effects to remain 
undetected (Raffaele et al., 2010; OECD TG 426). 
 
 
 
Figure 7:   DNT study design. A schematic representation of the exposure period and the parameters 
evaluated in the EPA guideline DNT study (Raffaele et al., 2010). 
 
The  OECD  TG  426  states  that  “the  Guideline  allows  various  approaches  with  respect  to  the 
assignment of animals exposed in utero and through lactation to functional and behavioural tests, 
sexual  maturation,  brain  weight  determination  and  neuropathological  evaluation.  Other  tests  of 
neurobehavioural function (e.g., social behaviour), neurochemistry or neuropathology can be added on 
a  case-by-case  basis,  as  long  as  the  integrity  of  the  original  required  tests  is  not  compromised”. 
Accordingly, there is considerable flexibility in TG 426 concerning the study design, such as the 
choice of behavioural tests included in the study, and also the design of the individual tests, e.g., 
strength of stimulus, intervals between testing trials and sessions, number of trials per day, etc. It is up 
to  expert  judgment  of  the  investigator  to  design  on  a  case-by-case  basis  the  most  sensitive  and 
appropriate test relevant for the exposure and toxicity of the compound under investigation. Although Developmental neurotoxicity potential of acetamiprid and imidacloprid 
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this flexibility introduces potential sources of variability in DNT study design, the integrity of the 
original  tests  should  not be  compromised.  Therefore,  the  studies conducted  for  regulatory  testing 
require a high level of transparency and a justified and detailed approach concerning the study design 
and methods used. 
 
A substantial amount of expertise is also required to interpret DNT study results, as well as to evaluate 
the reliability and relevance of DNT data for risk assessment. Expert judgment represents an integral 
and an important part of DNT testing and risk assessment. Therefore, to ensure proper use and the 
reliability  of  the  DNT  study  it  is  evident  that  good  guidance  documents  are  essential  to  assist 
investigators both within research and regulatory testing in the designing of DNT studies as well as in 
the interpretation of the results from different DNT tests.  
 
Notwithstanding this flexibility, according to some authors the DNT TG 426 represents so far the best 
available in vivo science-based testing protocol for assessing DNT potential to predict human health 
risk (Makris et al., 2009). The methodology used has been subjected to an extensive international 
validation, peer review and evaluation over the time. The reproducibility, reliability and sensitivity of 
the methods used have been demonstrated by using a wide variety of test substances. The results from 
DNT studies are used for hazard/risk assessment purposes because they meet the regulatory needs. In 
cases where data from a DNT study are not presented, safety factors may be employed to address the 
need for DNT data from a regulatory point of view (OECD Guideline Test No. 426, 2007; Raffaele et 
al., 2010).  
 
From 1998 to early 2006, approximately 114 DNT studies have been performed using either the US-
EPA guideline or the draft OECD guidelines. As of December 2008, 78 DNT studies were submitted 
to the EPA Office of Pesticide Programs (OPP) in support of pesticide registration. Although most of 
them evaluated organophosphorus insecticides, ACE and IMI were also tested (Raffaele et al., 2010). 
 
DNT guidelines are complex, time consuming, costly and not suitable for routine testing of high 
numbers of chemicals. Some concerns in terms of feasibility and animal welfare have been raised in 
the scientific literature. Although the protocol of the guidelines is well designed and covers a broad 
window of exposure, the critical phase for some effects might be missed and not all effects would be 
found. Furthermore, the interpretation of results is difficult because of knowledge gaps concerning 
normal brain development on the functional, structural and molecular levels, thus complicating risk 
assessment of compounds (Beronius et al., 2013). A number of issues related to the interpretation of 
DNT  studies  have  been  raised,  e.g.  excessive  variability  may  mask  treatment-related  effects  and 
conversely minor statistically significant changes can be considered as treatment-related when in fact 
they might fall within the normal range (Raffaele et al., 2008). All findings should be considered in the 
context of the study and interpreted in conjunction with other findings. Even statistically significant 
findings should be consistent with a pattern of effects (Tyl et al., 2008). 
 
It is not completely clear whether a negative DNT test is sufficient to exclude a DNT potential of a 
chemical compound. Although there are considerable data supporting the validity and sensitivity of the 
current US-EPA and OECD test guidelines, a number of activities have been and are underway to 
develop more rapid and efficient screening tools to predict developmental neurotoxicity of chemicals. 
In vitro and non-mammalian alternative systems-based models, along with in silico approaches could 
be scientifically robust methods suitable for the initial screening of chemicals for their potential to 
cause DNT. The data produced by alternative approaches may facilitate prioritisation of any further in 
vivo  testing.  However,  these  methods  will  need  to  be  formally  validated  to  meet  regulatory 
requirements and offer possible alternative options for certain endpoints of DNT TG 426.  
 
The in vitro and other alternative approaches could be used for a preliminary evaluation and for an 
initial  chemical  prioritisation  to  identify  “the  alerts”  that  may  have  the  potential  to  induce 
developmental neurotoxicity. Additionally, since the understanding of toxicity mechanisms becomes 
increasingly important in risk assessment, in vitro studies should be considered to obtain information 
on the cellular/molecular mechanisms involved in DNT that are very difficult to achieve using only in Developmental neurotoxicity potential of acetamiprid and imidacloprid 
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vivo approaches (Bal-Price et al., 2010, 2011). The relevance of the in vitro DNT testing for the in vivo 
situation  (both  toxicokinetics  and  toxicodynamic)  should  be  carefully  evaluated  exploiting  the 
available scientific evidence, but in general, the PPR Panel believes that in vitro tests currently used 
cannot substitute for in vivo DNT tests. To date, no in vitro test can be used to set health-based 
reference values.   
 
Following  the  provision  included  in  section  5.6.2  (“Developmental  toxicity  studies”)  of  the 
Commission  Regulation  283/2013,  on  data  requirements  for  active  substances,  the  PPR  Panel 
encourages  the  definition  of  clear  and  consistent  criteria  at  EU  level  to  trigger  submission  of 
mandatory  DNT  studies. These  could  include  development  of  an integrated DNT  testing  strategy 
composed  of  robust,  reliable  and  validated  in  vitro  assays  and  other  alternative  methods 
complementary  to  the  in  vivo  TG  426  for  prioritisation  or  screening  of  the  DNT  potential  of 
substances. Although this goal is probably beyond the remit of this Opinion, the PPR Panel however 
encourages the work in the field to reach international agreement on how DNT testing should be 
addressed. 
 
One of the most widely used in vitro systems in neurobiology is CGCs culture. The model is well 
characterised through its extensive use in studies of neuronal development, function and pathology. 
This in vitro system mainly consists of granule neurons (85 %), glial cells (15 %) and a few Purkinje 
cells. The primary cultures of CGCs are isolated from 1-10 days old pups as neurogenesis for the 
granule cells in cerebellum takes place postnatally, approximately between PND 0 and 10. The cells 
can be kept in culture for several weeks and are considered mature approximately after 10-12 days in 
culture.  For  DNT  studies  the  cells  should  be  exposed  to  the  test  chemical  before  they  reach 
morphological  and  physiological  maturation  (up  to  approximately  8-10  DIV)  to  cover  critical 
developmental processes (Bal-Price et al., 2010). 
 
Further development and improvement of the OECD TG 426 guidance documents should be carried 
out on periodic basis as new knowledge becomes available, leading to the improved tests based on the 
most recent science and technology. 
 
 
6.  Toxicological Assessments of Acetamiprid and Imidacloprid for Regulatory Purposes 
 
Both  ACE  and  IMI  were  assessed  under  Directive  91/414/EEC  for  their  inclusion  into  Annex  I. 
Discussions between the Rapporteur Member States (RMS), Co-RMS and other Member States were 
organised to review the Draft Assessment Reports (DARs) and the comments received on each section 
(identity  and  physical/chemical  properties,  fate  and  behaviour  in  the  environment,  ecotoxicology, 
mammalian toxicology, residues and analytical methods). 
 
For ACE Greece was designated to be the RMS and France the Co-RMS in the procedure. The EU 
Review report for this active substance was finalised in 2004 and ACE was authorised for use in the 
EU. As for IMI, Germany was designated as the RMS and submitted to EFSA the report of its detailed 
scientific examination. The EU review report was finalised in the meeting of the Standing Committee 
in July 2008 and the active substance was authorised for use in the EU. 
 
The toxicological data reported in section 5.1 and 5.2 belong to the assessment reports considered for 
the peer review of ACE and IMI in the EU. 
 
6.1.  Acetamiprid 
ACE is harmful by the oral route of administration; it has low acute dermal and inhalation toxicity; it 
is non irritant to the skin and the eyes of rabbits. It does not have sensitising potential. 
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The oral subacute and subchronic toxicity of ACE was studied in rats, mice and dogs. In a subchronic 
study in rats, the following doses were tested: 3.1, 6.0, 12.4, 50.8 and 99.9 mg/kg bw per day for males 
and  3.7,  7.2,  14.6,  56.0  and  117.1  mg/kg  bw  per  day  for  females.  NOAELs  were  identified  for 
decreased body weight (12.4 mg/kg bw per day) and for altered liver function parameters (14.6 mg/kg 
bw per day) based on increased total cholesterol and decreased glucose levels. ACE was not found to 
be genotoxic.  
 
The long term toxicity and carcinogenicity of ACE was studied in rats and mice. In the rat, the target 
organs were liver in males and females and kidney in males. Body weight was reduced and histo-
pathological findings were observed in liver and kidney. In a 2-year chronic study in rats, the dose 
levels were: 7.1, 17.5 and 46.4 mg/kg bw per day for males and 8.8, 22.6 and 60.0 mg/kg bw per day 
for females. The NOAEL was set at 7.1 mg/kg bw per day based on centrilobular hypertrophy at 17.5 
and 60 mg/kg bw per day in males and females, respectively. A NOAEL of 8.8 mg/kg bw per day was 
identified in female rats based on body weight reduction at 22.6 mg/kg bw per day. Microconcretions 
were observed in the renal papillae at 46.4 mg/kg bw per day in male rats. In the mouse study, the 
target organ was the liver. Body weight was reduced and hepatic histopathological findings were 
observed. However, NOAELs found for mice were higher than those for rats. ACE did not show a 
carcinogenic potential in rats and mice.  
 
In  pharmacological  studies  of  the  autonomic  nervous  system,  ACE  caused  a  decrease  in  blood 
pressure,  mydriasis  and  inhibition  of  gastrointestinal  movement.  Concerning  the  somatic  nervous 
system, muscle relaxation effects were observed. In the CNS, tremor and a decreased spontaneous 
activity were noted. An antidiuretic effect was observed in the urinary system. 
 
A number of toxicity tests were performed with ACE metabolites. None were genotoxic in a number 
of assays and they had oral LD50 levels higher than that of ACE. The same applies to 4 compounds 
that are present as impurities in technical ACE (WHO 2011). 
 
6.1.1.  Reproductive toxicity studies 
The reproductive toxicity of ACE was studied in rats throughout two generations. The doses tested 
were 0, 6.5, 17.9 and 52 mg/kg bw per day. In utero growth and post-natal growth throughout lactation 
of F1 and F2 pups were significantly decreased at the highest dose (a NOAEL of 17.9 mg/kg bw per 
day was identified based on a decreased postnatal survival at 52  mg/kg bw per day). A delay in 
preputial separation and vaginal opening, as well as reduced litter size, decreased pup viability and 
weaning indices were also observed. As regards to maternal toxicity, the NOAEL was set at 6.5 mg/kg 
bw per day based on decreased body weight at 17.9 mg/kg bw per day. The body weight of F2 pups 
during lactation, as well as viability and weaning indices were significantly decreased at 17.9 mg/kg 
bw per day, so the offspring NOAEL was set at 6.5 mg/kg bw per day. Overall, ACE did not show 
potential for reproductive toxicity. 
 
6.1.2.  Developmental toxicity studies 
Oral administration of ACE in pregnant rats and rabbits during the organogenesis period did not 
indicate  any  specific  potential  for  developmental  toxicity.  The  dose  levels  tested  in  the  rat 
developmental study were 0, 5, 16 and 50 mg/kg bw per day, with a maternal NOAEL of 16 mg/kg bw 
per day based on reduced body weight and food intake. The dose levels tested in the rabbit study were 
0, 7.5, 15 and 30 mg/kg bw per day and the maternal NOAEL was 15 mg/kg bw per day based on 
decreased body weight and food intake. In summary, no teratogencity and foetotoxicity was observed 
with rats and rabbits, and the foetal NOAEL was set at 50 and 30 mg/kg bw per day, respectively. 
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6.1.3.  Neurotoxicity studies 
ACE was studied for acute and subchronic behavioural neurotoxicity and neuromorphological effects 
in rats. The dose levels tested in the acute neurotoxicity study were 0, 10, 30 and 100 mg/kg bw. 
Clinical  signs  (tremors,  walking  and  postural  abnormalities,  decreased  grip  strength  and  reduced 
locomotor activity) were observed in both sexes at the highest dose. These effects were also shown by 
males at an intermediate dose on the day of treatment. In a subchronic study, the doses tested were 0, 
7.4, 14.8, 59.7 and 118 mg/kg bw per day for males and 0, 8.5, 16.3, 67.6 and 134 mg/kg bw per day 
for females. While decreased body weight and food intake were observed up to the top dose level, no 
evidence of irreversible neurotoxic effects was observed in the dose range assayed. The NOAEL for 
acute  behavioural  neurotoxicity  was  set  at  10  mg/kg  bw  based  on  decreased  locomotor  activity 
observed at 30 mg/kg bw, while the respective subchronic NOAEL was set at 14.8 and 16.3 mg/kg bw 
per day for males and females, respectively, based on non-neurotoxic endpoints. 
 
All together, neurotoxic effects occurred at approximately the same dose level as liver effects and 
general toxicity observed in the subchronic and reproduction studies. Also, there appears to be no 
difference in the dose ranges causing acute and prolonged neurotoxicity. 
 
6.1.4.  Developmental neurotoxicity (DNT) studies 
No DNT studies were submitted or available for the authorisation of ACE at EU level. 
 
Table 3:   Summary of the toxicological assessment of ACE (Greece, 2001). 
Acute toxicity  
Rat LD50 oral  in water: 417 mg/kg bw (male) R22 
314 mg/kg bw (female) 
Rat LD50 dermal  > 2000 mg/kg bw 
Short term toxicity  
Target / critical effect  Liver  
Lowest relevant oral NOAEL  12.4 mg/kg bw per day (200 ppm), 90 day rat study 
Long term toxicity and carcinogenicity  
Target/critical effect  Liver and kidney 
Lowest relevant NOAEL  7 mg/kg bw per day (160 ppm), 2 year rat study 
Carcinogenicity  No carcinogenic potential, treatment related mammary 
glands hyperplasia at 1000 ppm 
Reproductive toxicity  
Reproduction target / critical effect  Reduced postnatal survival and decreased pup weight 
at parental toxic doses 
Lowest relevant reproductive NOAEL  6.5 mg/kg bw per day (100 ppm) in rats 
Developmental target / critical effect  No teratogenicity or foetotoxicity was observed at the 
tested doses 
Lowest relevant developmental NOAEL   15 mg/kg bw per day in rabbits 
Neurotoxicity / Delayed neurotoxicity  
NOAEL acute 
 
NOAEL subchronic 
 
 
NOAEL developmental neurotoxicity 
10 mg/kg bw, based on reduced locomotor activity in 
the rat at high and medium dose 
200 ppm (14.8 and 16.3 mg/kg bw per day for males 
and  females  respectively)  based  on  reduced  body 
weight and food consumptions 
Not available 
Summary   Value  Study  Safety 
factor 
ADI  0.07  mg/kg  bw 
per day 
2 year rat study and 2-
generation  rat 
reproductive study 
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AOEL short term (Oral and systemic)  
 
 
AOEL long term (Oral and systemic) 
0.124 mg/kg bw 
per day 
 
 
0.07  mg/kg  bw 
per day 
13-week rat study 
 
 
 
2 year rat study and 2-
generation  rat 
reproductive study 
100 
 
 
 
100 
ARfD (acute reference dose)  0.1 mg/kg bw  Acute neurotoxicity rat 
study 
100 
 
6.2.  Imidacloprid 
IMI is moderately acutely toxic in rodents with oral LD50 values in the range of 380-650 mg/kg bw in 
rats and 130-170 mg/kg bw in mice. IMI has a low dermal and inhalation acute toxicity. It is neither a 
skin nor an eye irritant, and has no skin sensitising properties.  
 
In subchronic toxicity studies in rodents (98-day, 96-day, 91-day neurotoxicity studies in rats and a 
107-day  study  in  mice)  the  decreased  body  weight  or  body  weight  gain  was  the  most  sensitive 
parameter and the liver was the main target organ in dogs (28-day, 90-day, 1-year) and rats. Decreased 
body  weight,  hepatotoxicity  (clinical  chemistry  changes  and  histopathology  findings)  and 
histopathological degenerative changes in the testes were recorded. A NOAEL of 9.3 mg/kg bw per 
day was agreed for the 91-day neurotoxicity in rats based on decreased body weight. In some studies 
in dogs, liver and thyroid effects occurred (hepatocellular hypertrophy and follicular atrophy of the 
thyroid) as well as ataxia, tremors and/or mortalities were observed at the high dose only (180 mg/kg 
bw per day). The occurrence of ataxia and tremor suggested an effect on the CNS (NOAEL of 7.8 
mg/kg bw per day).  
 
In long term toxicity studies, the thyroid was the main target organ in rats, whereas in mice effects 
included  reduction  in  body  weight,  weak  hepatotoxicity  and  more  frequent  mineralisation  of  the 
thalamus. No evidence of an oncogenic potential of imidacloprid was found in both species. In a 
chronic toxicity study in rats, the following doses were tested: 0, 5.7, 17.1 and 50.6 mg/kg bw per day 
for male rats and 0, 8.3, 24.9 and 74.7  mg/kg bw  per day for female rats. The lowest NOAELs 
identified were 5.7 and 24.9  mg/kg bw per day, based on thyroid effects (increased incidence of 
colloid mineralisation) at 17.1 and 74.7 mg/kg bw per day in males and females, respectively. 
 
IMI did not show genotoxic potential. The available data on the acute toxicity to rats show that its 
metabolites 5-hydroxy IMI, nitrosimine and IMI 2-ketone are of lower toxicity than IMI. However, 
desnitro IMI, which is considered the most abundant metabolite, is more acutely toxic than IMI by 
about a factor of 1.4 (LD50 280 and 500 mg/kg bw, respectively). The remaining metabolites were less 
toxic than the parent compound, showing LD50 levels above 1000 mg/kg. No genotoxic potential of 
these metabolites has been reported. As occurs with nicotinoids, the desnitro metabolite is protonated 
under physiological pH, yielding a charged nitrogen moiety and raising its affinity for mammalian 
nAChRs. Since this metabolite is not more than twice as toxic as IMI, the risk to mammals from it is 
likely to be covered by the risk assessment for IMI.  
 
6.2.1.  Reproductive toxicity studies 
The effects of IMI on the reproductive parameters were studied in a one-generation (range-finding) 
and 2-generation rat studies. IMI did not show any potential for reproductive toxicity. The dose levels 
tested in the 2-generation study were 0, 8, 20 and 50 mg/kg bw per day. The offspring NOAEL was set 
at 20 mg/kg bw per day based on decreased preweaning body weight gain. The parental NOAEL was 
set at 20 mg/kg bw per day based on decreased body weight gain and food intake at 50 mg/kg bw per 
day.  
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6.2.2.  Developmental toxicity studies 
The embryotoxic effects of IMI were investigated in rats and rabbits. In the rat study, the dose levels 
tested were 0, 10, 30 and 100 mg/kg bw per day. The NOAEL was set at 30 mg/kg bw per day for 
both maternal and developmental effects based on increased incidence of wavy ribs (offspring) and 
decreased body weight gain and food intake (dams) at 100 mg/kg bw per day. In the rabbit study, the 
dose levels tested were 0, 8, 24 and 72 mg/kg bw per day and the offspring NOAEL was set at 24 
mg/kg bw per day based on decreased foetal weight, retarded ossification and increased prenatal litter 
loss at 72 mg/kg bw per day. The maternal NOAEL was set at 8 mg/kg bw per day based on decreased 
body weight gain and food intake at 24 mg/kg bw per day. Overall, there was no indication of a 
specific embryotoxic or foetotoxic potential. 
 
6.2.3.  Neurotoxicity studies 
Neurotoxic effects of IMI were investigated in acute and subchronic tests. Also a DNT study was 
performed in rats. The acute NOAEL was 42 mg/kg bw per day based on clinical signs and clearly 
reduced motor/locomotor activity at 151 mg/kg bw (dose level tested were 0, 42, 151 and 307 mg/kg 
bw per day). Most clinical signs appeared related to acute receptor-mediated cholinergic toxicity of 
IMI. In the 13-week neurotoxicity study, the dose levels tested were 0, 9.3, 63.3 and 196 mg/kg bw per 
day (rat males) and 0, 10.5, 69.3 and 213 (rat females). The NOAEL was 9.3 and 10.5 mg/kg bw per 
day (for rat male and females, respectively) based on a decreased body weight. Although minor effects 
were observed in the functional observational battery (FOB) at the highest dose tested, there was no 
convincing evidence of neurotoxicity. The subchronic NOAEL was 196 and 213 mg/kg bw per day for 
rat males and females, respectively. In the 28- and 90-day dog studies, tremor and trembling were 
observed as relevant acute effects with a NOAEL set at 7.8 mg/kg bw per day. 
Acute and prolonged neurotoxicity seem to occur at dose levels above those producing other toxic 
effects in the subchronic study. Moreover, acute neurotoxic effects seem to be more evident than those 
occurring upon prolonged exposure. 
 
6.2.4.  Developmental neurotoxicity (DNT) studies 
In a DNT study, summarised in the DAR prepared by Germany, the following dose levels were tested: 
0, 8, 20 and 56 mg/kg bw per day during gestation and approximately 0, 13, 30 and 80 mg/kg bw per 
day for the offspring. The NOAEL for pups was 30 mg/kg bw per day based on reduced preweaning 
body  weight  gain  and  decreased  motor/locomotor  activity  at  80  mg/kg  bw  per  day.  A  small  but 
statistically significant decrease in the caudate/putamen width was noted in female pups at the highest 
dose tested. The NOAEL for maternal toxicity was set at 56 mg/kg bw per day based on a transient 
decrease in food intake at the end of gestation and beginning of lactation. 
Table 4:   Summary of the toxicological assessment of IMI (Germany, 2005; EFSA 2008
10). 
Acute toxicity  
Rat LD50 oral  ~ 500 mg/kg bw Xn, R22 
Rat LD50 dermal  > 5000 mg/kg bw  
Short term toxicity  
Target / critical effect 
Body weight gain (rat, dog), liver (clinical chemistry and 
histopathological  findings:  rat,  dog),  trembling/tremor 
(dog) 
Lowest relevant oral NOAEL 
90-d rat: 14 mg/kg bw per day 
1-yr dog: 15 mg/kg bw per day 
 
Long term toxicity and carcinogenicity  
Target/critical effect  Body weight gain (rat, mouse), liver (blood chemistry: 
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rat, mouse; organ weight decrease: mouse ); thyroid 
(mineralisation in the follicular colloid: rat) 
Lowest relevant NOAEL  2-yr rat: 5.7 mg/kg bw per day 
2-yr mouse: 65.6 mg/kg bw per day 
Carcinogenicity  No evidence for carcinogenicity 
Reproductive toxicity  
Reproduction target / critical effect 
Parental bw gain decreased; fertility parameters 
unaffected; pup weight gain reduction at parentally toxic 
doses 
Lowest relevant reproductive NOAEL 
Rat, 2-generation: 
parental: 20 mg/kg bw per day 
reproduction: 50 mg/kg bw per day 
offspring: 20 mg/kg bw per day 
Developmental target / critical effect  Rat: maternal bw gain and food consumption decreased; 
developmental toxicity indicated by increase in skeletal 
variant (wavy rib). 
Rabbit: maternal bw gain and food consumption 
decreased, mortality; increased prenatal litter loss, 
reduced foetal weight, delayed ossification and skeletal 
anomalies at maternally toxic doses 
Lowest relevant developmental NOAEL  
Rat, maternal: 30 mg/kg bw per day 
Rat, developmental: 30 mg/kg bw per day 
Rabbit, maternal: 8 mg/kg bw per day 
Rabbit, developmental: 24 mg/kg bw per day 
Neurotoxicity  
NOAEL (acute neurotoxicity study)  42 mg/kg bw 
NOAEL (subchronic neurotoxicity study)  9.3 mg/kg bw per day 
NOAEL (developmental neurotoxicity study)  20 mg/kg bw per day (during gestation) 
 
Summary  
 
Value 
 
Study 
 
Safety 
factor 
ADI  0.06  mg/kg bw per 
day 
Rat, 2-year study  100 
AOEL  
 
0.08  mg/kg bw per 
day  
 
Dog, 28 and 90 days 
(acute effects) 
100 
 
ARfD (acute reference dose)  0.08 mg/kg bw 
 
Dog, 28 and 90 days 
(acute effects) 
100 
6.3.  The assessments of DNT studies by US-EPA 
a)  Acetamiprid 
In  a  DNT  study  compliant  to  US-EPA  guideline  OPPTS  870.6300  (Aug  1998),  acetamiprid  was 
administered to 25 mated female rats dosed by gavage at doses of 0, 2.5, 10 and 45 mg/kg/day from 
gestation day (GD) 6 through lactation day (LD) 21. The maternal NOAEL was 10 mg/kg per day 
based on decreased body weight and body weight gain during gestation at 45 mg/kg bw per day. At 
this high dose level the offspring showed treatment-related decreased body weights and body weight 
gains in males and females post-weaning, decreased pre-weaning survival (PND 0-1), and decreased 
maximum  auditory  startle  response  in  males.  Treatment  had  no  adverse  effects  on  clinical  signs, 
developmental landmarks, FOB, brain weight or brain morphology. No conclusions could be made on 
motor activity evaluation due to the low confidence in the data because of problems with the control 
data (i.e, the normal developmental pattern was not seen in control animals).The maximum auditory 
startle response amplitude was decreased 27 % (PND 20) and 40 % (PND 60) at 10 mg/kg bw per day, 
and it was decreased 42 % (PND 20) and 53 % (PND 60) at 45 mg/kg bw per day. However, only in 
the latter case the endpoint was considered as treatment-related. No conclusion was made on the 
effects of ACE on learning and memory because of the high variability in the data. 
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b)  Imidacloprid 
The same study summarised in the IMI DAR, and compliant to US-EPA guideline OPPTS 870.6300 
(Aug  1998),  was  available  to  US  EPA;  however,  differences  in  the  assessment  (e.g.,  dietary 
conversions, evaluation of some effects) were present. The average daily intake of IMI (administered 
to 30 parent female rat from GD 0 through PND 21) was 0, 8, 19.4, 54.7 mg/kg bw per day during 
gestation, and 12.8-19.5, 30.0-45.4 and 80.4-155.0 mg/kg bw per day during lactation. Treatment-
related effects for maternal animals were a decrease in food consumption for dams in the high dose 
group compared to controls during the third week of gestation and the first week of lactation. There 
was also a decrease in body weight gain during lactation days 0-7. The maternal NOAEL was 19.5 
mg/kg bw per day based on decreased food consumption and decreased body weight gain during 
lactation. 
 
Treatment-related effects for offspring were limited to the high dose group. Body weights of high-dose 
males and females were significantly decreased by 11-13 % (p <0.05) prior to and after weaning, with 
recovery (in females back to control levels by PND 50, in males to a 4 % difference that persisted to 
study termination). Body weight gains were also decreased 12-23 % during lactation, with recovery by 
PND 17. Overall motor activity was decreased on PND 17 in high-dose males (38 %) and females 
(31 %) and on PND 21 in females (37 %), although the differences were not statistically significant. 
The effects on motor activity were deemed as treatment related because of their magnitude and the 
occurrence at the high dose in both sexes during the period of exposure. High dose females at PND11 
had a 5.5% decrease in thickness of the caudate/putamen in comparison to controls (2.617 vs. 2.769 
mm). These females also had a 27.6% reduction in the thickness of corpus callosum (0.436 vs. 0.602 
mm).  The  decrease  in  the  caudate/putamen  width  persisted in  high  dose  female animals at  study 
termination (3.677 vs. 3.750 mm, p<0.05). The offspring NOAEL was 19.5 mg/kg bw per day based 
on decreased body weight and body weight gain, and decreased motor activity. The NOAEL for 
neuropathological  findings  in  females  was  estimated  to  be  5.5  mg/kg  bw  per  day  based  on  the 
application of a x10 safety factor to the LOAEL (54.7 mg/kg bw per day) since neuropathology was 
not performed at lower doses.  
 
 
6.4.  Comments of the PPR Panel on developmental neurotoxicity studies on acetamiprid and 
imidacloprid 
 
6.4.1.  Acetamiprid  
The DNT study on ACE was carried out within the US EPA assessment framework. The PPR Panel 
considers that, notwithstanding the claimed guideline compliance of this study, the data do not allow 
any  firm  conclusion  to  be  drawn  since  important  endpoints  such  as  motor  activity,  learning  and 
memory evaluation could not be properly assessed. Moreover, the PPR Panel notes that insufficient 
arguments seem to support the straight conclusion of the study reporting that (seemingly dose-related) 
reduced auditory startle responses in offspring first noted at 10 mg/kg bw was not related to treatment. 
Overall the study can only provide supportive evidence, but is inadequate for a proper characterisation 
of effects and dose-response relationship between ACE and developmental neurotoxicity. The PPR 
Panel recommends that, based on these uncertainties and methodological drawbacks, the NOAEL for 
DNT should be conservatively set at 2.5 mg/kg bw per day.  
 
6.4.2.  Imidacloprid  
The maternal NOAELs of the DNT study were 20 (EU) and 19.5 (US-EPA) mg/kg bw per day, based 
on transient effects on food intake (EU study only) and weight gain. The NOAEL for DNT in the EU 
study  was  20  mg/kg  bw  per  day  based  on  reduced  preweaning  body  weight  gain  and  decreased 
motor/locomotor activity at 56 mg/kg bw per day. Since the NOAEL and LOAEL for DNT are based Developmental neurotoxicity potential of acetamiprid and imidacloprid 
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on the dose levels calculated during gestation, the PPR Panel cannot rule out that such effects were at 
least partly induced by prenatal exposure. 
 
The NOAEL was estimated by California EPA at 5.5 mg/kg bw per day (from applying a 10-fold 
safety factor to the LOAEL) based on reduced thickness of the caudate/putamen and corpus callosum 
in females only. The PPR Panel notes that neuropathological examination at dose levels lower than 
54.5  mg/kg  bw  per  day  would  have  facilitated  a  more  accurate  assessment  of  the  NOAEL  for 
neuropathological  effects.  The  PPR  Panel  further  notes  that  in  the  EU  assessment  a  significant 
decrease in the caudate/putamen width was also present in females at 56 (prenatal exposure) mg/kg bw 
per  day  at  study  termination  and  it  is  unknown  whether  lower  dose  groups  were  analysed  for 
neuropathology. Thus, this finding in particular is consistent over time and could be considered as a 
specific effect. Accordingly, the NOAEL should be conservatively set at 5.5 mg/kg bw per day. 
 
The pathological changes observed in basal ganglia (caudate and putamen) and in corpus callosum 
may be associated with motor function control. In particular, putamen is connected with the globus 
pallidus  and  substantia  nigra  through  various  nervous  pathways.  Since  putamen  is  involved  in 
movement regulation and influence various types of learning, a decrease in thickness of this structure 
could be due to decreased number of neurons/glia ultimately leading to decreased motor activity. The 
neuronal nAChRs may be involved in some of this neuropathology, thus a possible link between 
morphological  and  functional  changes  should  be  taken  into  account.  Since  neuropathological 
assessment was first performed on PND 11, the timeline of the IMI developmental neurotoxicity could 
not be determined. Therefore, evidence from the DNT study in rats suggests that IMI may affect 
development  of  the  brain  structures,  although  the  current  data  may  be  insufficient  for  a  proper 
characterisation  of  effects  and  dose-response  of  IMI  developmental  neurotoxicity  during  pre-  and 
postnatal phases.  
 
The US-EPA deemed the study results of low concern because effects in pups are well characterised 
with a clear NOAEL and occurred in the presence of maternal toxicity (with the same NOAEL); thus, 
according to the US-EPA, no residual uncertainties for prenatal/postnatal toxicity were identified. 
However,  the  PPR  Panel  considers  that  the  neuropathological  findings  may  point  out  a  specific 
susceptibility of pups since the “estimated NOAEL” in pups is more than three-fold lower than the 
maternal  NOAEL.  Thus, a  better  characterisation  of  IMI  developmental  neurotoxicity  effects  and 
NOAEL is recommended. 
 
 
 
7.  The  reference  values  (Acceptable  Daily  Intake,  Acute  Reference  Dose  and  Acceptable 
Operator Exposure Level) currently agreed in the EU 
 
As regards ACE, neurotoxic effects occurred at approximately the same dose level as liver effects and 
general toxicity observed in the subchronic and reproduction studies. Also, no differences appear in 
the dose ranges causing acute and prolonged neurotoxicity, indicating that single exposure to ACE is 
neurotoxic. In contrast, for IMI acute and prolonged neurotoxicity seem to occur at dose levels above 
those producing other toxic effects in the subchronic study. Moreover, acute neurotoxic effects appear 
to be more evident than those occurring upon prolonged exposure. Overall, the two neonicotinoids 
seem to be somewhat different as far as neurotoxicity is concerned. 
 
As regards the current reference values for ACE, the ADI and long-term AOEL are 0.07 mg/kg bw per 
day  based  on  the  NOAEL  of  2  year  rat  study  and  2-generation  rat  reproductive  study  with  an 
uncertainty factor of 100. The short-term AOEL is 0.124 mg/kg bw per day based on a NOAEL of the 
90-day study in rats (12.4 mg/kg bw) with an uncertainty factor of 100. The ARfD is 0.1 mg/kg bw 
based on the NOAEL of 10 mg/kg bw in an acute rat neurotoxicity study with an uncertainty factor of 
100. Only the ARfD is based on a NOAEL for neurotoxicity. 
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The US-EPA DNT study clearly shows DNT effects of ACE (decreased maximum auditory startle 
response amplitude in males by 27 % at PND 20 and by 40 % at PND 60) at 10 mg/kg bw per day in 
the  absence  of  maternal  toxicity,  although  such  effect  was  not  considered  as  treatment  related. 
However, notwithstanding the claimed guideline compliance, this study has limited reliability since 
examination of motor activity, learning and memory was not adequately performed; thus, no reliable 
NOAEL values are available. The PPR Panel considers that, based on the indications provided by the 
US-EPA DNT study (no EU DNT study was performed), the current ARfD and short term AOEL may 
not  be  protective  enough  for  the  possible  DNT  of  ACE.  Moreover,  given  the  uncertainties 
aforementioned about the NOAEL setting in the one DNT study available for ACE, no conclusions 
can be reached as regards the ADI and long term AOEL. The PPR Panel recommends that, based on 
these uncertainties, the NOAEL for DNT should be conservatively set at 2.5 mg/kg bw per day instead 
of the originally considered 10 mg/kg bw per day. The occurrence in rat males only does not represent 
a  weakness  as  the  ontogeny  of  cholinergic  enzymes  is  different  in  males  and  females  (Loy  and 
Sheldon,  1987).  This  more  conservative  NOAEL  should  be  used  as  a  point  of  departure  for  the 
derivation of ADI, ARfD and AOELs, which should all be set at 0.025 mg/kg bw per day until new 
and more reliable DNT data are available. Then, the point of departure can be revised. 
 
As regards the current reference values for IMI, the ADI is 0.06 mg/kg bw per day based on the 
NOAEL of a 2-year rat study of 6 mg/kg bw with an uncertainty factor of 100. The ARfD and AOEL 
are 0.08 mg/kg bw based on the NOAEL of both 28- and 90-day dog studies (8 mg/kg bw) with an 
uncertainty factor of 100. Only the ARfD and AOEL are based on a NOAEL for neurotoxicity. 
 
The IMI DNT study showed a clear NOAEL for DNT effects  (decreased motor activity), around 
20 mg/kg bw per day; the same NOAEL was also observed for maternal toxicity, with the LOAEL for 
both effects being ∼55 mg/kg bw per day. The PPR Panel considers that, based on this NOAEL, the 
current ARfD may be protective enough for the possible DNT of IMI. However, in the US-EPA 
assessment, a NOAEL for neuropathological findings could not be determined and by assuming a 
LOAEL of 54.7 mg/kg bw per day, the NOAEL was estimated by California EPA as being 5.5 mg/kg 
per  day  by  applying  a  10-fold  default  factor.  This  “estimated  no  effect  level”  (ENEL)  might  be 
applicable  to  repeated  exposures  to  IMI  to  all  population  subgroups.  Because  decreases  in  brain 
structure dimensions could theoretically result from a single exposure in utero, the ENEL of 5.5 mg/kg 
bw per day could be used to estimate the risk of acute exposure to IMI in women of childbearing age. 
In this case, the current ARfD and AOEL may not be protective enough for potential DNT of IMI and 
should be conservatively lowered to the same level than the ADI (0.06 mg/kg bw per day). The ADI 
for IMI was estimated based on the chronic NOAEL of 5.7 mg/kg per day for thyroid effects in rats, 
which is sufficiently close to the ENEL of 5.5 mg/kg bw per day for decrease in the thickness of brain 
structures. Therefore it would be adequate for protection against the potential effects of IMI on the 
developing nervous system (California EPA, 2006). 
 
 
 
CONCLUSIONS AND RECOMMENDATIONS 
 
CONCLUSIONS  
 
The  PPR  Panel  concludes  that  both  ACE  and  IMI  show  some  indications  of  DNT  based  on  the 
available information, but further good quality in vivo data are needed following OECD TG 426, to 
more properly characterise a DNT potential and associated dose-response relationships. This would 
mainly apply to ACE, but should also be considered for IMI. New studies would benefit from a wider 
range of test concentrations in order to discriminate between direct and indirect effects. In addition, all 
dosed animals should be subjected to neuropathological analysis (including histology of the brain, in 
accordance with OECD TG 426).  
The data underlying the NOAEL used to set the reference values for ACE and IMI currently applied in 
the EU need to be further analysed and discussed, and a comparison with current risk assessment has 
to be taken into account to verify if there are uncertainties left.  Developmental neurotoxicity potential of acetamiprid and imidacloprid 
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Question  1:  Based  on  the  available  data  both  in  the  published  scientific  literature  and  in  the 
toxicological dossier submitted for approval, do acetamiprid and imidacloprid show developmental 
neurotoxic effects? 
Evidence from a DNT study of  IMI in rats  has revealed decreased body weights, reduced motor 
activity level and changes in dimensions of brain structures (reduction in the thickness of corpus 
callosum and a decreased width of caudate/putamen). The DNT study on ACE has showed decreased 
body weights, reduced pup viability and decreased maximum auditory startle response. However, no 
conclusion  can  be  drawn  for  ACE  owing  to  non-compliance  with  test  guidelines  (problems  with 
control data and high variability of some data) concerning the behavioural tests such as motor activity 
as  well  as  learning  and  memory  evaluation,  which  are  recognised  to  be  the  most  sensitive  DNT 
endpoints. Therefore, it is concluded that these two neonicotinoid compounds may affect neuronal 
development and function. However evidence is limited as a result of methodology issues and because 
neurotoxic effects were observed at the same dose levels eliciting maternal toxicity. 
 
Question  2:  Have  acetamiprid  and  imidacloprid  been  assessed  adequately  for  developmental 
neurotoxicity and if no, what further information would be of value in this assessment? 
Comprehensive  toxicological  databases  are  available  for  both  neonicotinoids.  Acute,  subacute, 
subchronic, chronic, mutageniticy, carcinogenity, reproduction, developmental and DNT studies have 
been carried out for the hazard characterisation of both compounds within regulatory frameworks. One 
DNT study has been performed for IMI and one for ACE (not complete and not adequately assessed 
for DNT); in both cases, studies were considered acceptable for regulatory purposes although they 
were not necessarily guideline compliant. However, the PPR Panel considers that the available data do 
not allow a full characterisation of developmental neurotoxicity of the two neonicotinoids. In the case 
of ACE, important neurodevelopmental endpoints such as motor activity and learning and memory 
have not been properly assessed. For IMI, data on neuropathology is available only for the highest 
dose tested and there is uncertainty about whether neuropathological changes occur at lower doses. 
The latter is of utmost importance since these changes may appear after a single dose of the active 
substance administered prenatally. 
 
Question 3: Do the existing health-based guidance values provide adequate protection against any 
potential developmental neurotoxicity of acetamiprid and imidacloprid and if not what values would 
be necessary to provide such protection? 
Based on the indications provided by the available DNT studies and the associated uncertainties in 
establishment of the corresponding NOAELs, the Panel considers that the current ARfDs may not be 
protective enough for the possible developmental neurotoxicity of acetamiprid and imidacloprid. The 
same uncertainties preclude from reaching any reliable conclusion as regards the ADI for acetamiprid. 
In turn, the ADI set for imidacloprid would be adequate for protection against its potential adverse 
effect on the developing nervous system. 
 
The PPR Panel recommends that a more conservative NOAEL of 2.5 mg/kg bw per day for ACE 
should be used as a point of departure for the derivation of ADI, ARfD and AOELs, which thus should 
be set at 0.025 mg/kg bw (per day). When new and more reliable DNT data are available, the point of 
departure can be revised.  
As the current ARfD and AOEL may not be protective enough for potential DNT of IMI, the Panel 
also recommends to conservatively lowering these reference values to the same level as the ADI (0.06 
mg/kg bw per day). 
 
Question 4: Do the approved neonicotinoids need further investigation to clarify the mechanism of 
action of the nAChRs? Should all the approved neonicotinoids be tested using the in vitro system 
mentioned in the publication of Kimura-Kuroda et al (2012)? 
Since  the  impaired  cholinergic  transmission  during  ontogenesis  may  be  a  component  of  some 
developmental disorders, additional studies with complementary DNT specific endpoints should be 
evaluated to have more solid information as to the potential DNT of neonicotinoids. The data provided 
by Kimura-Kuroda et al. (2012) indicate that further research on the action of neonicotinoids in the Developmental neurotoxicity potential of acetamiprid and imidacloprid 
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cerebellum may be warranted to fully understand the DNT potential of ACE and IMI. However, the 
assay presented by these authors covers only a very limited aspect of brain function, and its limitations 
prevent a current use as a screening tool in the regulatory context. However, further studies should be 
performed using the culture of a wider range of brain structures besides those derived from cerebellar 
cortex, which also express nAChRs, to thoroughly evaluate key developmental processes such as 
neuronal  and  glial  proliferation,  migration,  differentiation,  neurite  outgrowth,  synaptogenesis, 
networking, myelination and programmed cell death.  
 
The PPR Panel considers that it is necessary to develop mechanistic understanding of underlying 
molecular mechanisms and time frames of treatment with test substances to evaluate whether the 
observed effects in the study by Kimura-Kuroda et al. (2012) are reversible, to explain the meaning of 
the responses to the challenge by KCl and to define the more accurate estimation of concentrations of 
the test substance at the receptor site. To extend confidence in findings, provision of appropriate 
positive and negative controls and scrutiny of data for reliability and reproducibility are required. 
Accordingly, the in vitro system as proposed by Kimura-Kuroda et al. (2012) is not adequate for use 
as a tool for screening developmental neurotoxicants from a regulatory point of view. Considerable 
further characterisation is required before an improved protocol based on the one proposed by these 
authors can be used to assess its relevance for in vivo exposure. An integrated DNT testing strategy 
under a tiered approach, starting from validated in vitro assays to in vivo test, can be used to screen for 
pesticide DNT potential, including all neonicotinoids and their active (toxic) metabolites, provided 
that their toxicity is the consequence of binding to nAChR.  
 
 
 
RECOMMENDATIONS 
The PPR Panel proposes several recommendations for early consideration by risk managers, although 
they do not have to be necessarily implemented from a regulatory standpoint. These recommendations 
are related to both the knowledge gaps of the neonicotinoids and the DNT testing framework. 
 
•  The PPR Panel supports the requirements for new in vivo studies compliant with OECD TG 426, 
in particular for acetamiprid, in order to clarify current uncertainties and set robust dose-response 
relationships for DNT effects. 
•  New  studies  are  needed  to  clarify  whether  or  not  neonicotinoids,  and  their  active  (toxic) 
metabolites, can enter the brain across the BBB and to quantify any such capacity at all stages of 
development. The PPR Panel encourages the definition of clear and consistent criteria at EU level 
to trigger specific mandatory DNT studies, according to the provision included in section 5.6.2. 
(“Developmental  toxicity  studies”)  of  the  Commission  Regulation  No.  283/2013  on  data 
requirements  for  active  substances.  This  provision  emphasises  that  “When  indicated  by 
observations in other studies or the mode of action of the test substance, supplementary studies or 
information may be required to provide information on the postnatal manifestation of effects such 
as developmental neurotoxicity”. 
•  The PPR Panel supports the development of an integrated in vitro neurotoxicity testing strategy 
complementary to in vivo assays included into OECD TG 426 in order to screen the DNT potential 
of pesticides and other chemicals entering food chains, provided that the defined criteria to trigger 
mandatory DNT studies are met. The battery should be composed of robust, reliable and validated 
assays,  relevant  to  the  prediction  of  human  toxicity,  exploiting  the  wide  range  of  potential 
alternative  methods  (not  only  in  vitro),  and should support  a tiered and  cost-effective  hazard 
characterisation process tailored to the different knowledge bases for regulated chemicals. In vitro 
and  non-mammalian  alternative  systems-based  models,  along  with  in  silico approaches,  could 
provide  scientifically  robust  methods  suitable  for  the  initial  screening  or  prioritisation  of 
chemicals for their potential to cause DNT. Developmental neurotoxicity potential of acetamiprid and imidacloprid 
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•  The PPR Panel notes that the great interspecies differences observed in LD50 for acetamiprid and 
imidacloprid,  as  well  as  in  plasma  levels  after  non-lethal  acute  poisonings  by  these  active 
substances, could indicate the need to use human cells in culture for in vitro testing. 
•  Based on the reported subtle molecular changes in the structure of neonicotinoids that can lead to 
differential activation of nAChRs subtypes, more information would be needed on the potential 
developmental neurotoxic effects caused in vitro and in vivo by the active (toxic) metabolites of 
neonicotinoids, particularly those showing higher affinity for nAChRs than the parent compound.  
•  The role of nAChRs in neuronal differentiation and maturation should be evaluated in order to 
provide a mechanistic basis for the characterisation of possible developmental neurotoxic effects 
of  neonicotinoids.  Recommended  experimental  approaches  include  activating/inactivating  or 
blocking nAChR expression and using the natural agonist compound acetylcholine as a positive 
control. 
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GLOSSARY  
 
ADI (Acceptable Daily Intake): estimate of the amount of substance in food expressed on a body 
weight basis, that can be ingested daily over a lifetime, without appreciable risk to any consumer on 
the basis of all known facts at the time of evaluation, taking into account sensitive groups within the 
population (e.g. children and the unborn).  
 
AOEL  (Acceptable  Operator  Exposure  Level):  the  reference  value  against  which  non-dietary 
exposures  to  pesticides  are  currently  assessed.  It  is  intended  to  define  a  level  of  daily  exposure 
throughout a spraying season, year on year, below which no adverse systemic health effects would be 
expected. The AOEL is normally derived by applying an uncertainty factor (most often 100) to a No 
Observed Adverse Effect Level (NOAEL) (corrected if appropriate for incomplete absorption) from a 
toxicological study in which animals were dosed daily for 90 days or longer. Less often, the critical 
NOAEL comes from a study with a shorter dosing period (e.g. a developmental study). 
 
ARfD (Acute Reference Dose): estimate of the amount of substance in food and/or drinking water, 
expressed on a body weight basis, that can be ingested over a short period of time, usually during one 
day, without appreciable risk to the consumer on the basis of the data produced by appropriate studies 
and taking into account sensitive groups within the population (e.g. children and the unborn).  
 
Auditory startle reflex (ASR): it is a short-latency change in behaviour elicited by a sudden and 
intense acoustic stimulus. The ASR is noted as a sudden flinch or cessation of ongoing movement 
following the auditory stimulus. 
 
Basal ganglia: are a group of nuclei in the brains of vertebrates situated at the base of the forebrain 
and strongly connected with the cerebral cortex, thalamus and other brain areas. The basal ganglia are 
associated with a variety of functions, including voluntary motor control, procedural learning relating 
to routine behaviours or "habits," eye movements, and cognitive, emotional functions.   
 
Caudate/putamen: components of the basal ganglia. 
 
Corpus  callosum:  great  band  of  commissural  fibers  uniting  the  cerebral  hemispheres  of  higher 
mammals including humans.  
 
Developmental neurotoxicity: adverse effects of pre- and postnatal exposure on the development and 
function of the nervous system.  
 
Draft assessment report (DAR): initial evaluation of the dossier of an active substance prepared by a 
designated Member States. 
 
Desensitisation (of a receptor): Long-time response to receptor agonists due to high and prolonged 
levels of activation that produce a shift in receptor conformational equilibrium resulting in blockage of 
the receptor. The most common feature is a time-dependent change in ion current. 
 
Entorhinal cortex (Brodmann’s area 28): it constitutes the main interface between the hippocampal 
formation and the neocortex. It is located in the medial temporal lobe and together with perirhinal 
cortex (Brodmann‟s area 35) and hippocampus plays an important role in spatial learning and memory.  
 
Excitation (of a receptor):  When an impulse arrives at a presynaptic terminal it causes the release of a 
neurotransmitter and its subsequent diffusion across the synaptic cleft where it activates postsynaptic 
receptor sites opening specific ion channels. At an excitatory synapse, ionic fluxes through these 
channels tend to depolarize the membrane, while different patterns of ionic flux hyperpolarize the 
membrane at inhibitory synapses. 
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Glial proliferation: Following a peripheral nerve injury, the satellite glia cells around the damaged 
nerve  (e.g.,  Schwann  cells,  astrocytes  and  oligodendrocytes)  start  to  proliferate  for  repairing  the 
damaged tissue and restoring its function.   
 
Hazard characterisation: Qualitative and, wherever possible, quantitative description of the inherent 
property of an agent or situation having the potential to cause adverse effects.  
 
Health-based reference values: level of a substance that consumers and operators can be exposed to 
in the short- or long-term without an appreciable risk to their health. It is established on the basis of 
toxicological data showing the absence of an adverse effect with the correction by an uncertainty 
factor, conventionally of 100, to account for the differences between test animals and humans (factor 
of 10) and possible differences in sensitivity between humans (another factor of 10). It serves as 
reference for comparison with exposures occurring under realistic conditions over the short- or long-
term.  
 
Hippocampus: brain structure that plays an important role in the limbic system. It consists of gray 
matter covered on the ventricular surface with white matter, and that is involved in forming, storing, 
and processing memory and is also associated with learning and emotions. 
 
Myelin is an electrically insulating phospholipid layer that surrounds the axons of many neurons. 
 
Myelination: The acquisition, development, or formation of a myelin sheath around a nerve fiber. 
 
Neonicotinoid insecticides: class of insecticides with chemical structures similar to nicotine that share 
a common mode of action by binding to nicotinic acetylcholine receptors (nAChRs) in the central 
nervous system of insects. 
 
Neurite outgrowth: process during development, in which neurons make connections by growing in 
response to axon guidance cues; neurite outgrowth during nervous system development results in a 
network of synaptic connections between participating neurons. 
 
Networking (neuronal): connections and circuits between neurons.  
 
Nicotinic  acetylcholine  receptors (nAChRs):  receptors  that form  ligand-gated  ion  channels  with 
unique localisation in pre-, post-, and extrasynaptic membranes. They are found in the central nervous 
system (CNS) neurones of insects and in both the central and peripheral nervous systems of mammals 
as well as in neuromuscular junctions. 
 
OECD TG: the Organisation for Economic Co-operation and Development (OECD) Test Guidelines 
(TG) are a collection of the most relevant internationally agreed test methods used by government, 
industry and independent laboratories to determine the safety of chemicals and chemical preparations, 
including pesticides and industrial chemicals. 
 
Programmed cell death (or apoptosis): it is a form of cell death in which a programmed sequence of 
events leads to the elimination of cells without releasing harmful substances into the surrounding area. 
Apoptosis plays a crucial role in developing and maintaining the health of the body by eliminating old 
cells, unnecessary cells, and unhealthy cells. 
 
Synapse: structure at which a nerve impulse is relayed from the terminal portion of a neuron (axon) to 
the (dendrites of an) adjacent neuron. 
 
Synaptogenesis: formation of synapses between neurons. 
 
Thalamus:  is  a  midline  paired  symmetrical  structure  within  the  brains  of  vertebrates,  including 
humans. It is situated between the cerebral cortex and midbrain and it is involved in the relaying of Developmental neurotoxicity potential of acetamiprid and imidacloprid 
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sensory and motor signals to the cerebral cortex, and in the regulation of consciousness, sleep, and 
alertness. 